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ABSTRACT 
The fraction of exhaled nitric oxide (FENO) is a biomarker reflecting inflammation in 
the airways. Inter-individual variability of FENO is quite large in the general 
population. Physiological, biological, environmental and genetic factors contribute to 
the variability of FENO levels. 
The aim of this thesis was to utilize bioinformatics methods to comprehensively 
characterize genetic variation in the three nitric oxide synthase (NOS; NOS1, NOS2 and 
NOS3) genes using a tagging single nucleotide polymorphism (SNP) approach, and 
evaluate the genetic contribution to variation in levels of FENO in a general adult 
population. 
In paper I, a single-SNP association analysis between 49 SNPs in the three NOS genes 
and FENO was performed in 1733 adult subjects. Based on the associations, a list of 
top-ranked SNPs was selected and used in a forwarded stepwise analysis to identify a 
reduced set of strongest independently associated SNPs. Two SNPs (rs9901734 and 
rs3729508) in NOS2 and one SNP (rs7830) in NOS3 showed independent associations 
with levels of FENO. For NOS2 SNP rs9901734, subjects had 5.3% (95% CI 1.0% to 
9.7%) higher levels of FENO per G allele, and for rs3729508, subjects with CC or CT 
genotypes had 9.4% (95% CI 3.1% to 15.2%) higher levels compared with TT. Subjects 
with GT or TT in the NOS3 SNP rs7830 had 5.6% (95% CI 0.4% to 11.1%) higher levels 
of FENO as compared with those with GG. The effect of this SNP was stronger in 
subjects with asthma (21.9%, 95% CI 4.6% to 42.0%). In paper II the association 
between haplotypes in the NOS2 gene and FENO was investigated in 5912 adult 
subjects. Ten SNPs across the NOS2 gene were selected based on previously reported 
association to FENO. A stepwise linear regression analysis was performed in a forward 
approach to find a best subset of SNPs with the most significant (p≤0.005) association 
to FENO. These SNPs were then used to infer haplotypes. A generalized linear model 
was used for estimating the effects of all common haplotypes (haplotype frequency ≥ 
5%) on FENO using the most common haplotype as the reference group. Seven 
common haplotypes were inferred representing 84% of all haplotypes. One haplotype 
('ACCTT') was significantly associated with lower levels of FENO and three haplotypes 
('ACCTC', 'GGCTC' and 'GGCTT') were significantly associated with higher levels of 
FENO compared with the baseline haplotype (ACTCT), global p-value 3.8×10-28  for the 
haplotype distribution. The association of the haplotype 'ACCTT' with FENO varied by 
asthma status. 
Taken together, our findings suggest that NOS2 is the major NOS gene determining 
variability in levels of FENO in the healthy adult population, and also plays a role in 
subjects with asthma. In addition, a SNP in NOS3, and a particular haplotype in 
NOS2, appeared to contribute more strongly to the variation in FENO in subjects with 
asthma. This study also emphasizes the potential of combining SNP- and haplotype-
based approaches in identifying and characterizing the contribution of NOS genes to 
variation in FENO. 
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 SAMMANFATTNING PÅ SVENSKA 
Koncentrationen av kväveoxid i utandningsluft (FENO) är en 
biomarkör för inflammation i luftvägarna. Variabiliteten mellan 
individer i FENO är betydande i den allmänna populationen och 
faktorer som bidrar till variabiliteten är bl.a. fysiologiska, genetiska 
samt miljöfaktorer. 
 
Syftet med studierna i denna avhandling var att tillämpa metoder 
inom bioinformatik för att karaktärisera variationen hos de tre 
kväeoxidsyntasgenerna NOS1; NOS2 och NOS3 genom att använda en 
metod baserad på s.k. tag-SNPar (markör-varianter med förändring i 
en DNA bas) samt utvärdera det genetiska bidraget till variation i 
FENO-nivåer hos vuxna. 
 
I delarbete 1 utfördes först analys av sambandet mellan 49 SNPar i 
de tre NOS generna och FENO, en SNP i taget, i en studie-population 
av 1733 individer. Baserat på graden av association skapades en 
lista av rangordnade SNPar som sedan användes i en framåt stegvis 
regressionsanalys för att identifiera ett mindre antal SNPar med 
starkast oberoende association. Två SNPar (rs9901734 and 
rs3729508) i NOS2 och en SNP (rs7830) i NOS3 visade oberoende 
association med FENO-nivå. Individer med NOS2 SNP rs9901734 
hade 5.3% (95% CI, 1.0% – 9.7%) högre FENO-nivåer för varje G 
allel, och individer med genotyperna CC eller CT NOS2 för SNP 
rs3729508 hade 9.4% (95% CI 3.1% – 15.2%) högre FENO-nivåer 
jämfört med TT genotyp. Individer med GT eller TT genotyp i NOS3 
SNP rs7830 hade 5.6% (95%CI, 0.4% – 11.1%) högre FENO-nivåer 
jämfört med GG genotypen. Effekten av denna SNP var starkare hos 
individer med astma: 21.9%, 95% CI 4.6% – 42.0%. 
 
I delarbete 2 undersöktes sambandet mellan haplotyper i NOS2 
genen och FENO hos 5912 individer. Tio SNPar utspridda över hela 
NOS2 genen valdes ut baserat på tidigare kunskap om association 
med FENO. Sju haplotyper kunde urskiljas, och dessa 
representerade 84% av alla haplotyper. En haplotyp ('ACCTT)' var 
signifikant associerad med lägre FENO-nivåer och tre haplotyper 
('ACCTC', 'GGCTC' and 'GGCTT') var signifikant associerade med 
högre FENO-nivåer jämfört med referens-haplotypen ('ACTCT'), med 
 
ett globalt p-värde på 3.8×10-28 för haplotyp-distributionen. 
Associationen mellan haplotyp 'ACCTT' och FENO varierade med 
astma-status. 
 
Sammanfattningvis tyder resultaten på att NOS2 är den av  
NOS-generna som har störst inverkan på variabiliteten av FENO hos 
den friska, vuxna befolkningen, och även spelar en roll hos individer 
med astma. Dessutom indikerande resultaten att en SNP i NOS3 
(rs7830) samt en specifik haplotyp ('ACCTT') i NOS2 bidrog mer till 
variationen av FENO hos individer med astma. Analysen med 
haplotyper i NOS2 genen kunde påvisa det NOS2-relaterade bidraget 
till variationen i FENO starkare än analysen med individuella SNPar. 
Denna studie understryker också potentialen med att kombinera 
SNP- och haplotyp-baserade metoder för att identifiera och 
karaktärisera NOS-genernas bidrag till variation i FENO. 
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BACKGROUND 
Human genetics 
The human genome is made up of deoxyribonucleic acid (DNA), 
which is built up by the four nucleotides adenine (A), cytosine (C), 
guanine (G) and thymine (T). The DNA carries the genetic information 
which is passed on to the next generation. The four nucleotide bases 
pair up with each other so that 'A' always pairs with 'T', and 'G' 
always pairs with 'C'. Total length of the human genome is 
approximately 3.3 billion base pairs, which is distributed on 23 pairs 
of chromosomes. Segments of DNA along a region in the genome are 
called genes. Alternative forms of genes in certain positions, or loci, 
are called alleles. At each locus there are two alleles in an 
individual's pair of chromosomes, one from the father and one from 
the mother. The combination of the two alleles at each locus is called 
the genotype.  
Single nucleotide polymorphisms (SNPs) 
As much as 99.9% of the human DNA sequence is identical across 
populations, but there are also different arrangements in 0.1% of the 
DNA which make two individuals unique [1, 2]. Of the 0.1%, most of 
the arrangements (˃90%) are attributable to single nucleotide 
polymorphisms (SNPs). This type of polymorphism occurs when a 
single nucleotide (A, T, C, or G) in a specific position in the genome 
sequence is altered (Figure 1). SNPs occur with a minor allele 
frequency of at least 1% in the population [3], although the frequency 
can vary across populations and today also rare single nucleotide 
variants are often called SNPs. According to the current release of the 
SNP database (dbSNP) build 137 (June 2012) there are 53,558,214 
SNPs of frequency ≥1% in the human genome 
(http://www.ncbi.nlm.nih.gov/projects/SNP). On average one SNP in 
every 300 base pairs occurs throughout the genome [2, 4].  
The position of a SNP is important in determining the nature of effect 
of the SNP [5, 6]. For example, SNPs situated in the coding region of 
a gene may change an amino acid in the resulting protein, which in 
turn could directly change the protein structure or function. SNPs 
that occur in non-coding regions (introns or promoter) do not directly 
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involve amino acid change but they may alter gene expression or 
function of the protein, or be in linkage disequilibrium with (i.e. 
correlated with - see further below) a causative SNP or SNPs. 
Therefore, SNPs in a non-coding region are also important markers 
for assessing association with a trait or disease in genetic association 
studies. 
 
 
Figure 1. Illustration of a single nucleotide polymorphism (SNP), where a DNA 
sequence differs by a single nucleotide.  
 
Tag SNPs 
Rather than selecting all the SNPs in a gene, it is possible to select a 
small subset of SNPs that will provide good information on the total 
genetic variation in the gene/region. These SNPs are referred to as 
tag SNPs, and act as proxies for the rest of the SNPs, which can 
reduce genotyping cost considerably and simplify statistical analysis. 
Haplotypes 
A haplotype is a set of alleles situated at adjacent loci on the same 
chromosome. Often, the adjacent nucleotides within the same gene 
tend to be inherited together more often than expected by chance, a 
phenomenon called  linkage disequilibrium (LD) [7]. There are several 
measures of LD, including the correlation between two loci 
represented as r2 or degree of association between alleles (Dʹ) [8]. The 
value of r2 varies between 0 and 1, r2 = 1 means that the SNPs are 
completely correlated. Dʹ also varies between 0 and 1, Dʹ = 1 means 
complete allelic association.  
 
3 
Association studies of candidate genes 
Association studies are often performed to identify if one or more 
SNPs in a candidate gene are associated with a trait of interest. The 
trait of interest could be continuous (for example blood pressure) or 
binary (like many diseases; present or absent) [9-11]. Candidate gene 
association studies are hypothesis-driven and use data from e.g. a 
cohort or case-control set of unrelated individuals and can be cross-
sectional or longitudinal in nature. In case-control studies, 
essentially allele or genotype frequencies are compared among the 
cases and controls. In cohort studies, a linear association between a 
SNP and a continuous outcome can also be investigated. This thesis 
emphasizes the cross-sectional cohort study design. In order to 
estimate the effects of a SNP on a trait, different genetic models can 
be applied in the statistical analysis, as illustrated in Figure 2. Effect 
estimates are generally quantified based on number of the copies of 
minor allele (less common allele) [12]. When the combined effect of 
two minor alleles is equal to the sum of their individual effects, this 
is said to be an additive effect. When one or two copies of the minor 
allele have the same effect on a trait, the effect is said to be 
dominant. When two copies of the minor allele are required for effect, 
the effect is said to be recessive. 
 
 
 
 
 
 
 
 
Figure 2. Illustration of the most common genetic models. Blue line indicates a linear 
(additive effect) relationship between number of minor alleles and trait value. Red and 
green lines indicate non-linear relationship (recessive and dominant effects, 
respectively) between number of minor alleles and trait value. 
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studies. 
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Association studies of candidate genes 
Association studies are often performed to identify if one or more 
SNPs in a candidate gene are associated with a trait of interest. The 
trait of interest could be continuous (for example blood pressure) or 
binary (like many diseases; present or absent) [9-11]. Candidate gene 
association studies are hypothesis-driven and use data from e.g. a 
cohort or case-control set of unrelated individuals and can be cross-
sectional or longitudinal in nature. In case-control studies, 
essentially allele or genotype frequencies are compared among the 
cases and controls. In cohort studies, a linear association between a 
SNP and a continuous outcome can also be investigated. This thesis 
emphasizes the cross-sectional cohort study design. In order to 
estimate the effects of a SNP on a trait, different genetic models can 
be applied in the statistical analysis, as illustrated in Figure 2. Effect 
estimates are generally quantified based on number of the copies of 
minor allele (less common allele) [12]. When the combined effect of 
two minor alleles is equal to the sum of their individual effects, this 
is said to be an additive effect. When one or two copies of the minor 
allele have the same effect on a trait, the effect is said to be 
dominant. When two copies of the minor allele are required for effect, 
the effect is said to be recessive. 
 
 
 
 
 
 
 
 
Figure 2. Illustration of the most common genetic models. Blue line indicates a linear 
(additive effect) relationship between number of minor alleles and trait value. Red and 
green lines indicate non-linear relationship (recessive and dominant effects, 
respectively) between number of minor alleles and trait value. 
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It is likely that a single SNP is often neither necessary nor sufficient 
for influencing a trait, but instead a combination of SNPs (haplotype) 
may be responsible for the observed variation in a trait of interest 
[13]. However, resolving phase of haplotype (i.e. which chromosome 
each allele resides on) from observed SNP data is complicated in 
unrelated individuals, because most current genotyping technologies 
do not provide the phase of maternal or paternal chromosomes [14, 
15]. This ambiguity is referred to as haplotype uncertainty and there 
has been much effort to identify the most likely haplotypes for 
individuals based on unphased data, with different statistical 
approaches implemented in several bioinformatics tools [16-20]. 
Examples include the Bayesian approach [16], the parsimonious 
approach (the Clark algorithm) [18] and the maximum likelihood 
approach (Expectation-Maximisation (E-M) algorithm). The E-M 
algorithm is the most extensively used haplotyping algorithm and it 
is implemented in several programs for example Haplo.stats [21] , 
Hapassoc [22] and SNPHAP [23] . In brief, the E-M algorithm is a 
two-step iterative procedure (the expectation or E step and the 
maximisation or M step) of calculating the maximum likelihood 
estimates of the unknown parameters from observed data [24]. In the 
E step, posterior probabilities for each haplotype are estimated using 
the genotype information. In the M step, the estimates are iteratively 
updated until frequencies of haplotypes do not change. Then the 
inferred haplotypes can be incorporated into regression models to 
perform association analysis between haplotypes and a trait of 
interest. 
Nitric oxide 
Nitric oxide (NO) is an endogenous molecule present throughout the 
body. In the respiratory tract, NO plays multiple roles, both 
beneficial and harmful [25]. One of the beneficial effects is that it 
relaxes respiratory smooth muscles and acts as a bronchodilator. On 
the other hand, it is involved in various cytotoxic and pro-
inflammatory activities such as increased production of reactive 
oxygen species (ROS) [26], increased bronchial mucus secretion, 
eosinophilic inflammation [27] and increased airway 
hyperresposiveness [28].  
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NOS genes 
NO is synthesized from the amino acid L-arginine by specific NO 
synthase (NOS) enzymes [29]. There are three enzyme isoforms: 
neuronal NOS (nNOS; NOS1), inducible NOS (iNOS; NOS2) and an 
endothelial form (eNOS; NOS3). The three NOS isoforms are encoded 
by three distinct genes (NOS1, NOS2 and NOS3) located on different 
chromosomes (12, 17 and 7, respectively), and differentially 
expressed in different cells [25, 30]. All the NOS genes are expressed 
in airway epithelial cells [31]. NOS1 and NOS3 are largely 
constitutively expressed, resulting in a low basal synthesis of NO; 
show limited response to physiological stimuli; and are important for 
physiological functions in the airways [32]. NOS2, also called 
inducible NOS, is typically not constitutively expressed to any great 
extent, but its expression is strongly stimulated by various 
proinflammatory cytokines [33], resulting in a profoundly greater NO 
production in the induced state as compared with NOS1 and NOS3 
[34]. It has also been shown that NOS2 can be constitutively 
expressed depending on conditions or factors present in the airways 
[35]. Continuous exposure to irritants has also been reported to lead 
to rapid loss of NOS2 expression in airway epithelial cells in healthy 
subjects [35].  
Exhaled NO 
NO produced in the lung diffuses into the respiratory tract and is 
detectable in exhaled air. NO in exhaled air was first reported by 
Gustafsson and colleagues in human breath samples [36]. A couple 
of years later two independent studies reported that asthmatic 
patients have increased exhaled NO concentrations as compared to 
healthy individuals [37, 38]. Since then a great interest has been 
shown for exhaled NO in respiratory research and a substantial 
number of scientific articles have been published.  
Measurements of FENO 
In the clinical setting, a single-breath exhalation maneuver is the 
preferred procedure to measure NO in exhaled air. In the single-
breath exhalation procedure, individuals are asked to sit comfortably 
and inhale NO-free air via a mouthpiece to total lung capacity, then 
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exhale instantly against an oral pressure into the apparatus (Figure 
3). A computer screen attached to the apparatus displays exhalation 
flow rates together with pre-adjusted oral pressure so that subjects 
can maintain the pressure to achieve the desirable exhalation flow. 
This procedure is available for the NIOX® system (Aerocrine AB, 
Solna, Sweden) (Figure 3). This type of method was initially described 
by Kharitonov et al 1997 [39] and validated by the American Thoracic 
Society (ATS) and European Respiratory Society (ERS) [40, 41]. 
According to ATS and ERS, the NO concentration is recommended to 
be measured at an exhalation rate of 50 ml/second. However one can 
measure exhaled NO at different exhalation flow rates. In this thesis 
the term FENO (fraction of exhaled nitric oxide) is used for describing 
exhaled NO at the recommended flow rate of 50 ml/s. FENO is 
relatively easy to measure and highly reproducible in both healthy 
and non-healthy subjects of different ages [42, 43]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Measuring exhaled NO using the NIOX® system (Aerocrine AB, Solna, 
Sweden). 
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Factors influencing levels of FENO 
Increased levels of FENO have been reported in many inflammatory 
lung conditions including asthma, atopy, wheeze, and COPD, [37, 
44-46]. FENO levels in patients with asthma decrease after 
corticosteroid therapy [47-49] and correlate with sputum eosinophils 
[50] and skin prick test [51]. Decreased levels of FENO have also 
been reported in other inflammatory lung conditions like chronic 
fibrosis [52] and respiratory viral infections [53]. A number of other 
factors such as age, gender, height, atopy, smoking, respiratory tract 
infections and recent intake of nitrate-rich food are also important in 
determining levels of FENO [54-57]. In Swedish non-smoking adults 
the upper normal limit (corresponding to the 95th percentile) for 
FENO varies between 24 and 54 parts per billion (ppb) (geometric 
mean of FENO is 16.6 ppb) [54] depending on age, height and atopy. 
In an earlier population-based analysis in our study population, age 
and height accounted for 11% of the variability in FENO [54]. 
Cigarette smoking leads to reduction of FENO levels [58, 59] and the 
value of FENO for assessing airway inflammation in smokers is not 
clear; however some studies have documented higher levels of FENO 
in smokers with asthma compared to healthy smokers [60, 61]. 
In addition to the factors described above, genetic factors also 
influence variation in levels of FENO. In a Norwegian twin study, 
genetic factors explained 60% of the variability in FENO [62]. Several 
genome-wide linkage studies have demonstrated linkage to 
chromosomes 7, 12 and 17 for asthma- and atopy-related 
phenotypes [63-68]. The NOS1, NOS2 and NOS3 genes are located in 
clusters of genes on chromosome 12, 17 and 7 respectively. Few 
studies have examined associations between polymorphisms in the 
NOS genes and FENO levels, and the results of these studies have 
been inconsistent [69-74]. In adults with asthma an association 
between AAT repeats in intron 20 in NOS1 and higher FENO levels 
was reported [69]. The same AAT repeat was associated with asthma 
or atopy but not with FENO in children [70, 73]. A recent population-
based cohort study of American children has reported significant 
associations for FENO with genetic variants of NOS2 but not with 
NOS1 or NOS3 [75]. This result for NOS2 has also been replicated in 
adults [74] , but in contrast to the American children study, the 
investigators also reported an association between SNPs belonging to 
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NOS3 and FENO levels. A recent gene expression study suggested 
that expression of NOS2 in humans is more strongly correlated with 
FENO than is NOS3 [76]. For NOS3, an association of the T allele of 
the missense variant G894T (rs1799983) to lower FENO levels was 
reported in adult asthmatics [72] but not in Chinese children with 
asthma [73]. 
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AIMS 
The overall aim of the thesis was to comprehensively characterize 
genetic variation in the three nitric oxide synthase (NOS; NOS1, 
NOS2 and NOS3) genes using a tagging SNP approach, and evaluate 
the genetic contribution to variation in levels of FENO in a general 
adult population. 
Specific aims in paper I and II 
Paper I 
 To understand which of the three NOS genes are most 
important for determining variation in levels of FENO. 
 
 To investigate if such genetic effects on FENO were different in 
healthy individuals as compared to asthma or atopy. 
 
 To investigate whether any of the NOS SNPs related to FENO 
were also associated with asthma, atopy or lung function. 
Paper II 
 To investigate if the association between haplotypes in the 
NOS2 gene and FENO is stronger and more distinct than 
single SNP associations. 
 To investigate possible effect modifications by asthma status 
at the haplotype level. 
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MATERIALS AND METHODS 
Study population 
This project is based on the population-based ADONIX (Adult Onset 
Asthma and Exhaled Nitric Oxide) cohort of randomly selected men 
and women aged 25-75 years at the time of sampling, and living in 
the city of Gothenburg and surrounding municipalities in Sweden 
during the 2001 - 2008. During the period from April 2001 to 
December 2004 the ADONIX study was established as a sub-project 
linked to the population-based cohort INTERGENE [77]. There was a 
break during 2004 because of data preparation. Thereafter, 
recruitment into the ADONIX study cohort was continued from 2005 
to 2008. 
In paper I, only 2001-2003 data was used, whereas for paper II the 
full 2001-2008 cohort was used. 
The ADONIX study was approved by the local Ethics Committee at 
Gothenburg University, Sweden. 
Data collection 
A postal questionnaire and invitation to a clinical examination was 
sent to 14554 randomly selected subjects. The overall participation 
rate of the invited cohort was 46%, 2487 participated during 2001-
2003 and 4192 participated during 2005 - 2008. The postal 
questionnaire included questions on respiratory symptoms, smoking 
habits and medical history. The clinical examination included 
anthropometric measurements (height and weight), FENO 
measurements, lung function measurements, and blood samples. 
Measurement of FENO 
In this project, FENO was measured by the NIOX® Nitric oxide 
monitoring system (Aerocrine AB; Stockholm, Sweden) (Figure 3) at 
exhalation flow rates of 50 mL/s (±10%) against an oral pressure of 5 
cm H2O in accordance with the ATS and ERS recommendations [40, 
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41]. Individuals were asked not to eat or drink 1 hour before FENO 
measurements. The FENO measurements were obtained before 
spirometry because repeated spirometric maneuvers may affect 
FENO values [78]. 
During the period from June 2001 to January 2003 measurements 
were performed in triplicate, and in duplicate from February 2003 to 
2008, within 10% deviation, according to the later published revised 
ATS/ERS recommendations [40, 41]. The mean of these 
measurements was used as a stable measure of FENO. 
Asthma 
In the present study, asthma was defined based on a positive answer 
to at least one of the questionnaire items: 'Have you ever had 
asthma?'; 'Have you ever had asthma diagnosed by a doctor?'; 'Have 
you had an attack of asthma during the last 12 months?'; 'Have you 
had asthma during the past month?'  
Atopy 
In this study, atopy was defined as the presence of specific serum 
Immunoglobulin E (IgE) antibodies ≥0.35 kU/L to one or more of 
eight common inhaled allergens (dog, cat, horse, timothy grass, 
birch, mugwort, house dust mite, and cladiosporum) [79]. IgE 
antibodies against these common inhaled allergens were determined 
by the Phadiatop test (Pharmacia Diagnostics; Uppsala, Sweden) 
according to the manufacturer's instructions. 
Lung function 
The lung function parameters forced expiratory volume in 1 second 
(FEV1) and forced vital capacity (FVC)) were determined by a dry 
wedge spirometer (Vitalograph; Buckingham, UK). The predicted 
values for spirometric variables (FEV1 and FVC) were calculated 
based on age, sex and height [79]. 
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Table 1. Baseline characteristics of the ADONIX population, as well as the 
geometric FENO levels overall and in subgroups, in paper I and II. 
  Paper I Paper II 
  
Subjects 
(n=1737) Mean(±SD) 
Subjects 
(n=5633) Mean(±SD) 
Age, years 1737 49 (13.6) 5633 52 (11.7) 
Height, cm 1737 172 (9.1) 5633 173 (9.2) 
FEV1/FVC ratio 1312 0.8 (0.1) 5520 0.9 (0.1) 
FVC (% predicted) 1312 97.1 (12.6) 5520 110 (15.5) 
FEV1 (% predicted) 1312 93.8 (13.6) 5520 103 (15.3) 
     
FENO levels, ppb 
    All  1737 15.9 (1.8) 5633 16.4 (1.8) 
     Men  853 17.1 (1.7) 2686 18.2 (1.8) 
     Women  884 14.7 (1.7) 2947 14.9 (1.8) 
     Smokers 325 11.2(1.8) 995 11.4 (1.8) 
     Non-smokers 1412 17.5(1.7) 4674 17.6 (1.7) 
                           
Asthma  298 17.3 (1.9) 726 17.7 (2.1) 
Atopy 434 18.4 (1.8) 1340 18.9 (1.9) 
FENO: fraction of exhaled nitric oxide; ppb: parts per billion.  
FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second;    
Genetic analysis  
DNA extraction 
Genomic DNA was extracted from blood using a magnetic separation 
of nucleic acid method (mag DNA Isolation Kit: AGOWA GmbH, 
Berlin, Germany). All the samples were stored in -80 . The samples 
were diluted with water to a concentration of 5ng/µl before 
genotyping.  
Genotyping methods 
DNA samples were genotyped using the Sequenom MassARRAY 
method (Sequenom, San Diego, California USA) or a competitive 
allele specific PCR system, KASPar (KBioscience, Hoddesdon, 
Hertfordshire, UK). 
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Genotyped subjects 
The number of SNPs and individuals genotyped in papers I and II 
varies. In paper I, 54 SNPs were genotyped in 2125 individuals. Of 
these, 2084 (98%) were of European origin and included in paper I. 
In total 1737 subjects had FENO, genotype, and covariate 
information and were included in the final analysis set. 
In paper II, 10 SNPs were genotyped in 6340 individuals. Of these, 
5963 (94%) were of European origin and included in paper II. Among 
these, 5633 participants had FENO values and constituted the final 
analysis set. 
SNP selection 
In Paper I, 54 SNPs in the three NOS genes (25 NOS1, 17 NOS2 and 
12 NOS3) were selected based on the reported association with 
respiratory disease phenotypes or as tag SNPs (Tables 2, 3 and 4). 
Six SNPs were selected based on previously reported association with 
FENO or asthma or other respiratory diseases. The remaining 48 
tagSNPs were selected using the HapMap phase III European 
ancestry data (www.hapmap.org) with pair-wise r2 for SNPs ≥0.8 at 
minor allele frequency ≥5%, across the genes including 100 kb 
upstream and 50 kb downstream of each gene. 
In paper II, 10 SNPs in the NOS2 gene were selected based on 
previously reported association with levels of FENO (Table 3), and 
genotyped in the extended ADONIX 2001-2008 cohort dataset [75, 
80]. Six SNPs (rs9901734, rs2297514, rs2248814, rs12944039, 
rs3729508 and rs2779248) resulted from the main findings from our 
previous analysis [80]. The remaining four SNPs (rs4796017, 
rs2297520, rs9895453 and rs10459953) were selected from the 
Salam et al Southern California Children’s Health Study [75]. 
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Table 1. Baseline characteristics of the ADONIX population, as well as the 
geometric FENO levels overall and in subgroups, in paper I and II. 
  Paper I Paper II 
  
Subjects 
(n=1737) Mean(±SD) 
Subjects 
(n=5633) Mean(±SD) 
Age, years 1737 49 (13.6) 5633 52 (11.7) 
Height, cm 1737 172 (9.1) 5633 173 (9.2) 
FEV1/FVC ratio 1312 0.8 (0.1) 5520 0.9 (0.1) 
FVC (% predicted) 1312 97.1 (12.6) 5520 110 (15.5) 
FEV1 (% predicted) 1312 93.8 (13.6) 5520 103 (15.3) 
     
FENO levels, ppb 
    All  1737 15.9 (1.8) 5633 16.4 (1.8) 
     Men  853 17.1 (1.7) 2686 18.2 (1.8) 
     Women  884 14.7 (1.7) 2947 14.9 (1.8) 
     Smokers 325 11.2(1.8) 995 11.4 (1.8) 
     Non-smokers 1412 17.5(1.7) 4674 17.6 (1.7) 
                           
Asthma  298 17.3 (1.9) 726 17.7 (2.1) 
Atopy 434 18.4 (1.8) 1340 18.9 (1.9) 
FENO: fraction of exhaled nitric oxide; ppb: parts per billion.  
FVC: Forced vital capacity; FEV1: Forced expiratory volume in 1 second;    
Genetic analysis  
DNA extraction 
Genomic DNA was extracted from blood using a magnetic separation 
of nucleic acid method (mag DNA Isolation Kit: AGOWA GmbH, 
Berlin, Germany). All the samples were stored in -80 . The samples 
were diluted with water to a concentration of 5ng/µl before 
genotyping.  
Genotyping methods 
DNA samples were genotyped using the Sequenom MassARRAY 
method (Sequenom, San Diego, California USA) or a competitive 
allele specific PCR system, KASPar (KBioscience, Hoddesdon, 
Hertfordshire, UK). 
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Genotyped subjects 
The number of SNPs and individuals genotyped in papers I and II 
varies. In paper I, 54 SNPs were genotyped in 2125 individuals. Of 
these, 2084 (98%) were of European origin and included in paper I. 
In total 1737 subjects had FENO, genotype, and covariate 
information and were included in the final analysis set. 
In paper II, 10 SNPs were genotyped in 6340 individuals. Of these, 
5963 (94%) were of European origin and included in paper II. Among 
these, 5633 participants had FENO values and constituted the final 
analysis set. 
SNP selection 
In Paper I, 54 SNPs in the three NOS genes (25 NOS1, 17 NOS2 and 
12 NOS3) were selected based on the reported association with 
respiratory disease phenotypes or as tag SNPs (Tables 2, 3 and 4). 
Six SNPs were selected based on previously reported association with 
FENO or asthma or other respiratory diseases. The remaining 48 
tagSNPs were selected using the HapMap phase III European 
ancestry data (www.hapmap.org) with pair-wise r2 for SNPs ≥0.8 at 
minor allele frequency ≥5%, across the genes including 100 kb 
upstream and 50 kb downstream of each gene. 
In paper II, 10 SNPs in the NOS2 gene were selected based on 
previously reported association with levels of FENO (Table 3), and 
genotyped in the extended ADONIX 2001-2008 cohort dataset [75, 
80]. Six SNPs (rs9901734, rs2297514, rs2248814, rs12944039, 
rs3729508 and rs2779248) resulted from the main findings from our 
previous analysis [80]. The remaining four SNPs (rs4796017, 
rs2297520, rs9895453 and rs10459953) were selected from the 
Salam et al Southern California Children’s Health Study [75]. 
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Table 2. Genotyped SNPs in the NOS1 gene in the population.  
rs number 
 Alleles 
(Major/Minor) 
MAF 
 (%) 
HWE  
p-value   
Call 
rate 
Previous 
publications 
Reported 
association 
rs2682826 G/A 27.6 0.67 96.1 Leung et al 2005 Increased IgE 
rs816347 G/A 8.7 0.17 97.4   
rs2293054 G/A 27.9 0.47 97.1   
rs2293055 G/A 10.0 0.89 98.2   
rs9658350 A/G 19.2 0.52 92.7   
rs6490121 A/G 32.1 0.47 97.2   
rs2293050 C/T 40.4 0.48 98.0   
rs7977109 A/G 48.4 0.10 93.4   
rs7314935 G/A 12.4 0.58 97.6   
rs9658354 A/T 40.1 0.65 98.7   
rs532967 G/A 18.9 0.87 98.0   
rs7310618 C/G 10.9 0.26 98.0   
rs553715 G/T 40.1 0.27 98.3   
rs2077171 C/T 30.1 0.30 97.1   
rs545654 T/C 47.5 0.96 98.3   
rs12578547 T/C 23.9 0.03 95.1   
rs12424669 C/T 12.3 0.26 98.5   
rs1552227 C/T 28.4 0.68 98.4   
rs499262 C/T 18.5 0.28 90.9   
rs693534 G/A 39.6 0.96 97.6   
rs3782218 C/T 16.1 0.31 92.2   
rs1123425 A/G 42.7 0.55 97.9   
rs17509231 C/T 13.6 0.68 97.3   
rs9658253 C/T 19.1 0.53 98.2   
rs41279104 C/T 13.4 0.34 96.9   
MAF: Minor allele frequency; HWE: Hardy-Weinberg Equilibrium; IgE: Immunoglobulin E.  
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Table 3. Genotyped SNPs in the NOS2 gene in the population. 
rs number Alleles (Major/Minor) 
MAF 
(%) 
HWE 
p-value 
Call 
rate 
  Previous 
publications 
 Reported 
association 
rs4795051 C/G 42.7 0.37 98.8 Salam et al 2011 FENO 
rs9901734* C/G 23.2 1 98.6 Dahgam et al 2012 FENO 
rs2255929 T/A 43.1 0.52 98.2 Hancock et al 2006 PD 
rs2297514† T/C 39.4 0.22 97.9 Dahgam et al 2012 FENO 
rs2297515 A/C 14.0 0.48 97.4   
rs2248814† G/A 41.0 0.73 98.0 Dahgam et al 2012 FENO 
rs2314810 G/C  5.1 1 98.5   
rs12944039† G/A 20.2 1 98.0 Dahgam et al 2012 FENO 
rs2297520 C/T 40.2 1 98.6 Salam et al 2011 FENO 
rs4795067 A/G 37.0 0.6 98.2   
rs3729508* C/T 40.5 0.58 98.3 Dahgam et al 2012 FENO 
rs9895453 T/C 47.7 0.55 98.6 Salam et al 2011 FENO 
rs944725 C/T 41.8 0.55 96.4   
rs8072199 C/T 48.2 0.11 96.2   
rs2072324 C/A 18.9 0.34 96.1   
rs3730013 G/A 31.6 1 98.0   
rs10459953 G/C 35.6 0.14 97.8 Salam et al 2011 FENO 
rs2779248† T/C 38.6 1 97.7 Dahgam et al 2012 FENO 
rs2301369 C/G 38.2 0.88 96.5   
MAF: Minor allele frequency; HWE: Hardy-Weinberg Equilibrium; * Top SNPs 
associated with FENO in multi-SNP analysis and † additional strongest p-values for 
association with FENO in single-SNP analysis in our previous work [80], and included 
in paper II. PD: Parkinson's disease.  
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Table 4. Genotyped SNPs in the NOS3 gene in the population. 
rs number Alleles (Major/Minor) 
MAF 
(%) 
HWE 
p-value 
Call 
rate 
Previous 
Publications 
Reported 
association 
rs10277237 G/A 21.7 0.62 98.0   
rs1800779 A/G 35.3 0.12 97.6   
rs2070744 T/C 36.1 0.12 98.2   
rs3918226 C/T  7.6 0.3 98.4 Holla et al 2006 Asthma 
rs3918169 A/G 16.8 1 97.3 Holla et al 2006 Asthma 
rs3793342 G/A 16.0 0.59 98.0   
rs1549758 C/T 28.5 0.44 98.2 Holla et al 2008 Asthma 
rs1799983 G/T 29.2 0.35 98.2   
rs3918227 C/A  9.4 0.89 98.0   
rs3918188 C/A 36.0 0.34 97.4   
rs1808593 T/G 19.9 0.88 96.1   
rs7830 G/T 38.0 0.17 98.0   
MAF: Minor allele frequency; HWE: Hardy-Weinberg Equilibrium. 
Genotype coding and genetic models 
Consider a SNP with two alleles 'A' and 'a'; 'A' is major allele and 'a' is 
minor allele. Possible genotypes of the SNP are 'AA', 'Aa' and 'aa'. 
Under the additive genetic model, each SNP was coded to 0 (AA), 1 
(Aa) and 2 (aa), where each number indicates the number of copies of 
the minor allele. Under the dominant model the SNPs were coded as 
0 (AA) and 1 (Aa+aa); under the recessive model each SNP was coded 
as 0 (AA+Aa) and 1 (aa). The other suggested models which were also 
investigated in paper I, over-dominant (heterozygote risk; 0 (AA+aa) 
and 1 (Aa))  and co-dominant or genotype-specific, which allows for 
unconstrained patterns of risk for Aa and aa, coded with two 
indicator variables with AA as common baseline: 1 (Aa) vs. 0 (AA+aa), 
and 1 (aa) vs. 0 (AA+Aa). 
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Statistical analysis 
Call rates, MAF and Hardy–Weinberg disequilibrium (HWE) test p 
values were calculated using the R statistical package 'SNPassoc' 
[81]. 
 
Since FENO had a skewed distribution, the values were log-
transformed prior to analyses. All the analyses were adjusted for age, 
sex, height, atopy and smoking habits. Results are presented as 
percentage change in the geometric mean of FENO across groups of 
subjects. Single-SNP association analysis was performed with the R 
statistical package 'SNPassoc' [81]. Regression analyses were done 
using SAS version 9.3 (SAS Institute; Cary, NC, USA). 
SNP association analysis 
In paper I, association analyses between each SNP and FENO were 
performed using the additive, dominant, recessive, over-dominant 
and co-dominant genetic models. 
First, single-SNP association analysis was performed to identify and 
rank the associations. Next, we performed an analysis in two stages 
using forward stepwise multiple linear regression analysis to identify 
a reduced set of the strongest independently associated SNPs and 
the most appropriate genetic model for each final SNP. The stepwise 
regression model approach was also used in paper II.  
Analyses stratified by asthma or atopic status, respectively, were also 
performed for the main effect models. The relationship between the 
genotypes that had effect on FENO and lung function, asthma or 
atopy was also investigated using a linear or logistic regression 
model. 
Haplotype association analysis 
The 'haplo.stats' package which implements the E-M algorithm was 
used for inferring common haplotypes (haplotype frequencies ≥5%) in 
the NOS2 gene [17]. A generalized linear model using the 'haplo.glm' 
function implemented in the 'haplo.stats' package was used for 
estimating the effect of all common haplotypes on levels of FENO, 
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using the most common haplotype as the reference group, assuming 
an additive genetic model. The effect of haplotype on FENO by asthma 
status was investigated, by including product terms between the 
haplotypes and asthma in the main effect model.  
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RESULTS 
Paper I 
Of the 54 genotyped SNPs, 4 SNPs had a genotype call rate below 
95% and one showed departure from HWE (p=0.03) (Tables 2-4) and 
these SNPs were excluded from analysis. Genotype distribution for 
49 SNPs in the three NOS genes (20 NOS1, 17 NOS2, and 12 NOS3) 
were in HWE (Tables 2-4). Figure 4 shows the results of single-SNP 
association between 49 SNPs in the three NOS genes and FENO 
levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Single-SNP association between FENO and 49 SNPs in the NOS1, NOS2 and 
NOS3 genes, by five different genetic models. Each circle represents the minus log10 of 
the p value for one single NOS SNP for each genetic model. The horizontal dotted line 
shows a statistical significance level at p value 0.05. ↑=SNPs with p≤0.2 from additive 
model. ♦=SNP with p≤0.05 from at least one non-additive model. 
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within the gene or, where sufﬁcient LD structure is present, lso
in adjacent genes.37 We further extended this approach by
adding a second stepwise regression step to aid in identifying
most appropriate genetic models for each SNP that we observed
to be associated.
Some potential weaknesses of the present study should be
noted. According to the instrument manufacturer (Aerocrine
AB) the variability in FENOmeasurements is around 3 ppb. This
variability would induce some level of independen misclassiﬁ-
cation unrelated to genetic variation, and will on average tend to
slightly bias our results towards the null. A broad deﬁnition of
asthma was used, based on a questionnaire response with at
least one positive answer to one of several related questions
regarding asthma diagnosis and current active asthma, which
carries a potential risk of misclassiﬁcation. However, such
misclassiﬁcation of asthma is likely to be non-differential with
Figure 1 Single-SNP association between fraction of exhaled nitric oxide (FENO) and 49 single nucleotide polymorphisms (SNPs) in the three nitric
oxide synthase (NOS) genes (NOS1, NOS2, NOS3), by five different genetic models. Each circle represents the minus log10 of the p value for one
single NOS SNP for each genetic model. The horizontal dotted line shows a statistical significance level at p value 0.05. [¼SNPs with p#0.2 from
additive model. D¼ SNP with p#0.05 from at least one non-additive model.
204 J Med Genet 2012;49:200e205. doi:10.1136/jmedgenet-2011-100584
Complex traits
 
 
 
 
Figure 4. Single-S P association between FENO and 49 SNPs in the NOS1, NOS2 
and NOS3 genes, by five different genetic models. Each circle represents the minus 
log10 of the p value for one single NOS SNP for each genetic model. The horizontal 
dotted line shows a tati tical significance level at p value 0.05. ↑=SNPs with p≤0.2 
from additive model. Δ=SNP with p≤0.05 from at least one non-additive model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
In the multi-SNP model, two SNPs in NOS2 (rs9901734 and 
rs3729508) and one in NOS3 (rs7830) showed independent 
associations with levels of FENO (Table 5). No independent 
significant association was seen for any of the SNPs in the NOS1 
gene on FENO. 
 
  
Table 5. Association of SNPs in the NOS genes with FENO among adults. 
Multi-SNP model. 
Gene/SNP  
Genetic 
model   
 Prevalence 
n = 1737 
  Difference in  
    p-value    Genotypes  
  FENO (%),  
  95% CI 
NOS2 
         
rs9901734  Additive   CC (ref) 59% 
 
    0.016 
  
CG    36%    5.3 (1.0-9.7)       
  
GG   5%   10.7(1.9-19.5) 
 
         
rs3729508  Dominant   TT(ref)  17% 
 
    0.004 
    CC+CT 83%   9.4 (3.1-15.2) 
 
NOS3 
Dominant   GG (ref)    40%       0.034 rs7830 
    GT+TT 60%   5.6 (0.4-11.1)   
FENO: Fraction of exhaled nitric oxide; NOS: Nitric oxide synthase; 
SNP: Single nucleotide polymorphism. 
 
When we stratified by asthma or atopy, the effect estimate for NOS2 
rs9901734 in ‘healthy’ subjects (ie, no asthma, wheeze or atopy) was 
marginally strengthened and remained significant. The NOS2 
rs3729508 estimate was slightly attenuated, while for NOS3 rs7830 
little effect was seen (Figure 5). In subjects with asthma or atopy, the 
effect estimates were slightly weaker for rs9901734 and slightly 
stronger for rs3729508, although the difference was not significant. 
For NOS3, the rs7830 effect estimate was considerably stronger in 
subjects with asthma (21.9%, 95% CI 4.6% to 42.0%) and 
significantly different from healthy subjects (p for interaction= 0.01), 
but less so in atopic subjects. 
No significant association was found between the FENO-associated 
NOS2 and NOS3 SNPs and asthma, atopy or lung function. 
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Figure 5. Association between FENO and SNPs in NOS2 and NOS3 in subjects with 
asthma, atopy and in healthy individuals.  
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Paper II 
Genotype distribution for the 10 SNPs in the NOS2 gene were in 
HWE. Call rate was ≥95 for all the SNPs (Table 3). 
The 5 most significant SNPs in the NOS2 gene resulting from the 
stepwise analysis were selected for haplotype analysis (Figure 6). 
 
 
Figure 6. Location of the studied SNPs on chromosome 17. Boxed rs numbers indicate 
the SNPs most strongly associated with FENO resulting from the stepwise analysis. 
 
A total of 7 common haplotypes were identified, representing 84% of 
all haplotypes. The most common haplotype alleles were present in 
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DISCUSSION 
Our findings that both NOS2 and NOS3 are involved in regulating 
FENO levels are novel, and build a coherent picture with other 
emerging evidence. The NOS2 gene is the major NOS gene 
determining variability in FENO in healthy subjects, and also plays a 
role in subjects with asthma. This is consistent with a priori 
expectations, since experimental evidence has suggested that NOS2 
encodes for the major enzyme producing NO in exhaled breath [76]. 
In a population-based study in children, conducted in California also 
provided evidence of association for SNPs in NOS2 with FENO levels, 
supporting the idea that polymorphisms in NOS2 are the most 
important NOS gene determinants of FENO [75]. On the other hand, 
the present study found that the genetic contribution of NOS3 was 
more prominent in subjects with asthma. NOS3 has previously been 
suggested to contribute to the variation FENO levels in asthma [72, 
73]. These results have now also been confirmed by a recently 
published study conducted on adults with and without asthma, 
which suggested that NOS2 is the major NOS gene determining 
variability in FENO in healthy subjects and NOS3 in asthma patients 
[74]. In the present study no association was observed between SNPs 
in NOS1 and FENO. This is well in line with gene expression data, 
where NOS2 is highly expressed in the human lung, while NOS3 is 
expressed to lesser extent and NOS1 is undetectable [76]. 
We also used haplotypes to describe the total common genetic 
variation in the NOS2 gene. Seven common haplotypes were 
identified, constituting 84% of all haplotypes based on our defining 
SNP set. The common haplotypes in NOS2 provided much stronger 
association with FENO than single-SNP associations (global p-value 
3.8×10-28 for the haplotype distribution). The association of FENO 
with one haplotype in NOS2 clearly differed between subjects with 
and without asthma. Our findings generally support the findings in 
children with and without asthma by Salam et al who also reported 
that several haplotypes in NOS2 were associated with higher levels of 
FENO [75]. However, Salam et al used a population-based sample of 
children that were partly of European and non-European ancestry 
(non-Hispanic white and Hispanic white), and another set of SNPs to 
infer all possible haplotypes that occurred to describe variation in 
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levels of FENO. So neither the two study populations nor the 
haplotype analysis methods are entirely comparable. 
In single-SNP analyses, individuals with all of the studied FENO-
associated NOS2 and NOS3 SNPs (21% of population) had on average 
35% higher FENO than individuals with none of the FENO-
associated NOS2 and NOS3 SNPs (4% of the population). Likewise in 
the haplotype analyses, individuals with the haplotype that was 
associated with higher FENO (H6; frequency 10%) had on average 
21% FENO than individuals with the haplotype that was associated 
with the lowest FENO levels (H3; frequency 9%). In the same 
population as in this study, current smokers had 30% higher FENO 
than non-smokers, and subjects with asthma had 16% higher FENO 
than healthy subjects [54]. When trying to use a single FENO 
measurement for guiding diagnosis, an important obstacle is the 
large variation in ‘normal FENO value’, and our results suggests that 
this is partly due to genetic differences. We have previously 
endeavoured to establish normal values for FENO based on FENO 
measurement from the same population as in this study [54]. 
Since the variability in FENO related to genetic variation is of a 
similar magnitude to that related to smoking or asthma, it should 
potentially be possible to improve the usefulness of FENO for 
assessing inflammation if the genetic background of subjects could 
be known. 
Most of the SNPs we used in this study are not located in coding or 
promoter regions. Their function remains unknown. They may 
influence gene expression, directly affecting variation in FENO. 
Alternatively, they may be in LD with other coding or functional SNPs 
that actually affect variation in FENO. Nevertheless, the 
comprehensive SNP selection and detailed analysis in this study has 
contributed to a better understanding of which regions within these 
genes that may be of relevance for the effects seen.  
The data used in this thesis come from a population-based cohort of 
adults (the ADONIX study), where potential participants were 
randomly selected from the Swedish national population register. 
The participation rate was 46%, which is less than one would ideally 
expect. The limited participation rate raises questions regarding the 
representativity of the study sample to the underlying population. A 
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non-attendance analysis within the INTERGENE-study, the same 
study from which the ADONIX-participants originate, was performed 
based on comparisons with registry data [82]. This study showed 
that non-participants were more likely to be young, men, less 
educated, have lower income and to be of non-Nordic origin, which is 
in line with similar more recent studies [83]. However, the potential 
response bias is not likely to be related to the genetic background of 
participants, and hence of less relevance for the present study and 
its generalizability. 
Misclassification of outcome is an important issue to consider. In 
this thesis we used a stationary chemiluminescence analyzer (the 
NIOX® system) which is widely used for measurement of FENO. The 
method is easy to use and reproducible in healthy individuals as well 
as in subjects with asthma [54, 84]. According to the instrument 
manufacturer (Aerocrine AB, Solna, Sweden) the variability in FENO 
measurements is around 3 ppb. This variability would induce some 
level of misclassification, but this is likely to be unrelated to genetic 
variation (non-differential misclassification), and would therefore on 
average tend to slightly bias our results towards the null. 
A relatively broad definition of asthma was used, based on a 
questionnaire response with at least one positive answer to one of 
several related questions regarding asthma diagnosis and current 
asthma symptoms. This type of approach clearly carries a potential 
risk of misclassification. In general, however, such misclassification 
of asthma is likely to be non-differential with regard to genotypes, 
and thus would not account for the genetic associations we observed, 
but may have contributed to decreased statistical power in analyses 
involving the asthma and for detecting a true effect modification in 
the analyses stratified by asthma status. 
In this thesis, we used a combination of two different approaches for 
selecting SNPs. The first approach is based on literature looking at 
the NOS genes as candidate genes, and second is a tag SNP approach 
to complement the first and achieve good genetic coverage. In the 
first approach, we chose SNPs that previously have been reported to 
be associated with airway inflammation, asthma and other 
respiratory diseases; because they might be causative or involved in 
FENO variation. In the second, tag SNP approach, we attempted to 
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select an optimal set of SNPs to capture variation in unmeasured 
SNPs and also to reduce genotyping cost. It is not necessary to 
genotype all SNPs in a gene since the high correlations between 
many SNPs (LD) can give rise to redundant information, and it 
becomes more costly to genotype all SNPs [85].  
Population stratification is a common confounding issue in genetic 
association studies. It implies confounding by ethnicity, in which 
allele frequencies which vary between ethnically different populations 
within the study sample may lead to spurious associations, resulting 
from differences in genetic ancestry which also affect the studied 
phenotype [86]. In this study we attempted to limit potential 
confounding by population stratification by including only subjects 
that were homogeneous with respect to ethnic background  
(i.e. subjects reporting European country of birth). Therefore, our 
results are not necessarily generalizable to a population of non-
European ancestry. Genotype error, especially genotyping large 
samples of data in different laboratories can increase rates of 
misclassification [11, 87]. In this study the genomic DNA samples 
were genotyped in two different laboratories using two different 
methods. To increase the validity of the genetic data used, we 
employed several quality control methods, for example adequate call 
rate and assessment of HWE (i.e. stable distribution of frequencies of 
the genotypes in a population). SNPs with call rate ≤95% were 
excluded from the study, as were SNPs that were clearly and 
significantly out of HWE.  
In our analysis strategy, we used a stepwise regression analysis with 
a forward approach performed in two stages. We focused on forward 
selection rather than backward selection due to the high number of 
variables (8 SNPs, each with five different genetic models), since this 
approach makes the modeling more practical and easily interpretable 
than starting by elimination from a very large set of SNPs [88]. In the 
context of genetic association studies, stepwise regression analysis 
has been proposed as a useful method to select the most relevant 
typed variants, and thereby potentially also capture effects of 
untyped causal functional polymorphisms within the gene or, where 
sufficient LD structure is present, also in adjacent genes [89]. We 
further extended this approach by adding a second stepwise 
regression step to aid in identifying most appropriate genetic models 
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for each SNP that we observed to be associated. Given the correlation 
structure that often exists in SNP data the forward selection may fail 
to identify some important associations, because some SNPs never 
get to enter the model and in the process may become redundant 
because of the relationship between SNPs added in and earlier step 
and SNPs added later. However, the "missed" SNPs with strong 
results in the single-SNP analysis but not included in our main 
findings were further considered in haplotype analyses in paper II.  
Haplotype analysis, which may provide additional information 
beyond individual SNP analysis about the genetic basis of complex 
traits and can be helpful in understanding the unit of biological 
function, has become of more widespread interest in finding causal 
connections in candidate genes studies [90]. Haplotype frequencies 
were estimated using the E-M algorithm, an established method for 
inferring haplotypes that estimates haplotypes assuming HWE. In 
our data all the SNPs that were used in the analyses were in HWE, or 
at least not significantly out of HWE. The inferred frequencies of the 
haplotypes are therefore likely to be reasonably unbiased. In 
addition, haplotypes were inferred from a set of SNPs with previously 
reported association with FENO rather than by just selecting random 
tag SNPs. Constructing haplotypes from a subset of informative SNPs 
reduces the haplotype dimensionality and increases power for 
detecting associations as compared to separate analysis of individual 
SNPs [13, 91, 92]. Although significant associations were found also 
for individual SNPs in this study, the haplotype analysis revealed 
very strong associations, and the haplotype model provided a much 
stronger global p value (3.8×10-28) for association than individual 
SNPs. 
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CONCLUSIONS 
This thesis provides strong evidence that the NOS2 and NOS3 genes 
contribute to variation in FENO and identifies relevant SNPs and 
haplotypes, and it extends this knowledge for the first time to an 
adult population.  
The findings further suggest that the two genes may play different 
roles in healthy subjects and in subjects with asthma. The NOS2 
gene is the major NOS gene determining variability in FENO in 
healthy subjects and also plays a role in subjects with asthma.  
NOS3 contributes to variability in FENO largely in subjects with 
asthma.  
The analysis of haplotypes in the NOS2 gene described the NOS2-
related contribution to variation in FENO more strongly than the 
analysis of individual SNPs, and haplotype-defining SNPs were 
located relatively far apart in the gene, suggesting that there are 
likely to be several genetic regions within NOS2 that are responsible 
for variation in FENO. Furthermore, one haplotype in the NOS2 gene 
contributed to the variation in FENO much more strongly in subjects 
with asthma than in healthy subjects, whereas the other haplotypes 
showed less contribution. 
An independent effect was also found for one NOS3 SNP and this 
effect was stronger in subjects with asthma, indicating that NOS3 
may play a more prominent role for FENO variation in subjects with 
asthma, and suggesting involvement of different pathways of NOS2 
and NOS3 for contribution to difference in FENO in subjects with 
asthma and without asthma.  
This study also emphasizes the potential of combining SNP- and 
haplotype based approaches for identifying and characterizing the 
contribution of NOS genes to variation in FENO.  
Potential clinical implications are interesting to consider, given that, 
the variability in FENO related to the NOS genes is approximately 
similar to that of non-genetic factors. These findings may help 
provide improvements in predicting normal FENO levels in the 
general population. However, at present genotyping is not a routine 
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test, and it is not possible to evaluate measured FENO levels in the 
scope of presence/absence of NOS polymorphisms in a clinical 
setting. With further development the genotyping techniques this 
may, however, become feasible, and would enhance the 
interpretation of an individual FENO value.  
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ORIGINAL ARTICLE
Single nucleotide polymorphisms in the NOS2 and
NOS3 genes are associated with exhaled nitric oxide
Santosh Dahgam,1 Fredrik Nyberg,1,2 Lars Modig,3 A˚sa Torinsson Naluai,4
Anna-Carin Olin1
ABSTRACT
Background Polymorphisms in nitric oxide synthase
genes (NOS1, NOS2, and NOS3) have been suggested
to have a major impact on fraction of exhaled nitric oxide
(FENO), a biomarker of airway inflammation. However,
the genetic contribution of NOS polymorphisms to FENO
is not fully understood. The aim of this study was to
investigate comprehensively the association between
single nucleotide polymorphisms (SNPs) in all three NOS
genes and FENO in an adult population, and to assess
whether such associations are modified by asthma or
atopy.
Method In 1737 adults from a Swedish general
population sample, FENO was measured and genetic
variation in the NOS genes was assessed using 49 SNPs.
The genetic effect of NOS polymorphisms on FENO,
asthma, and atopy was estimated using multiple
regression methods.
Results In a multi-SNP model based on stepwise
regression analysis, two SNPs in NOS2 and one in NOS3
showed independent associations with levels of FENO.
For NOS2 SNP rs9901734, subjects had 5.3% (95% CI
1.0% to 9.7%) higher levels of FENO per G allele, and for
rs3729508, subjects with CC or CT genotypes had 9.4%
(95% CI 3.1% to 15.2%) higher levels compared with TT.
For NOS3 SNP rs7830, subjects with GT or TT had 5.6%
(95% CI 0.4% to 11.1%) higher levels than GG; the
genetic effect of this SNP was stronger in asthmatics
(21.9%, 95% CI 4.6% to 42.0%).
Conclusion These results suggest that NOS2 is the
major NOS gene determining variability in exhaled nitric
oxide in the healthy adult population, while NOS3 may
play a more important role in asthmatic adults.
INTRODUCTION
The fraction of exhaled nitric oxide (FENO) is
a non-invasive biomarker of airway inﬂammation
and a useful clinical tool for diagnosing and moni-
toring asthma.1 2 It is easy to measure and results
can be obtained in real-time (online), making it an
attractive method in the clinical management of
asthma. We have recently reported that increased
FENO levels predict new onset of respiratory
symptoms in a follow-up cohort.3 One obstacle,
however, to more widespread utility of FENO is
that the inter-individual variation in healthy
subjects is relatively large, and there is limited
knowledge about factors explaining this variation.
FENO levels are increased in subjects with asthma4
and atopy5 and appear to be related to eosinophilic
airway inﬂammation, such that 26% of the
variation in FENO could be explained by the
concentration of eosinophils in induced sputum in
a large study of asthmatic adults.6 In healthy adult
subjects, the main predictors of FENO are atopy,
height, and age, which together explain 11% of the
variability of FENO.7
In addition, genetic factors are suggested to have
a major impact on FENO variability. In a Norwe-
gian twin study, genetic factors explained 60% of
the variability in FENO.8 This study also observed
that FENO and airway hyperresponsiveness share
a common genetic basis.
Nitric oxide (NO) is synthesised by speciﬁc NO
synthase (NOS) enzymes, with three distinct
isoforms: neuronal NOS (nNOS; NOS1), inducible
NOS (iNOS; NOS2), and endothelial NOS (eNOS;
NOS3).9 10 All three NOS isoforms are expressed in
the lung.11 The NOS1 and NOS3 genes are consti-
tutively expressed resulting in a low basal synthesis
of NO,12 13 whereas expression of NOS2 seems to
be more strongly regulated by gene transcription
factors such as nuclear factor k B (NFKb), resulting
in an increased NO production.14 A recent gene
expression study suggested that expression of
NOS2 in humans is signiﬁcantly more detectable
and highly correlated with FENO than NOS3.15
Few studies have examined associations between
polymorphisms in the NOS genes and FENO levels
and, the results of these studies have been incon-
sistent.16e20 A reported association between AAT
repeats in intron 20 in NOS1 and higher FENO
levels in asthmatic adults16 was not replicated in
asthmatic children.17 18 20 A recent population based
study found tag single nucleotide polymorphisms
(SNPs) in NOS2 to be signiﬁcantly associated FENO
and the association was stronger in asthmatic chil-
dren.21 For NOS3, an association of the missense
variant, G894T (rs1799983), to lower FENO levels
was reported in adult asthmatics but not in Chinese
children with asthma.19 20
The aims of this study were to examine
comprehensively the role of SNPs in all three NOS
genes on the levels of FENO in a large adult cohort;
and to study whether any risk variants might be
associated with asthma, atopy or lung function,
and if the genetic effect on FENO is modiﬁed by
these respiratory phenotypes.
METHODS
Study population and design
The present study is a part of the ADONIX (adult-
onset asthma and exhaled nitric oxide) study
cohort of 2200 randomly selected men and women
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aged 25e75 years from the city of Gothenburg and surrounding
municipalities in Sweden, recruited between June 2001 and
December 2003.7 22 All participants received a postal question-
naire and an invitation to a clinical examination, which included
FENO measurements, lung function measurements (forced
expiratory volume in 1 s (FEV1) and forced vital capacity (FVC))
as well as blood samples. Participants were classiﬁed as never,
former, and current smokers, based on questionnaire informa-
tion. In the present study, asthma was deﬁned as a positive
response to at least one of the questionnaire items: (1) self
reported asthma; (2) doctor diagnosed asthma; (3) asthma
attack during the last 12 months; (4) current asthma symptoms
during the month preceding clinical examination. Atopy was
deﬁned as the presence of speciﬁc serum IgE antibodies
($0.35 kU/1) to any of eight common inhaled allergens (dog,
cat, horse, timothy grass, birch, mugwort, house dust mite, and
cladiosporum) as determined by the Phadiatop test (Pharmacia
Diagnostics; Uppsala, Sweden).23 24 Spirometry was performed
with a dry wedge spirometer (Vitalograph; Buckingham, UK)
according to American Thoracic Society (ATS) guidelines, and
FEV1/FVC ratio and percentages of predicted FEV1 and FVC
were calculated based on age, sex, and height.25 Genomic DNA
was extracted from blood using a magnetic separation of nucleic
acid method (mag DNA Isolation Kit: AGOWA GmbH, Berlin,
Germany). Participants of non-European origin (5%) were
excluded from the study to avoid genetic heterogeneity. Of those
reporting European country of origin and included in the study,
the vast majority (96%) were of Swedish origin.
Exhaled nitric oxide measurements
FENO was measured before spirometry at an expiratory ﬂow
rate of 50 ml/s using a chemiluminescence method (NIOX-
system; Aerocrine AB, Stockholm, Sweden) according to ATS/
European Respiratory Society (ERS) recommendations. Three
exhalations were registered during the study period June 2001 to
January 2003, and two exhalations during February 2003 to
December 2003, according to revised ATS/ERS recommenda-
tions,26 27 and the mean concentration of these was used.
SNP selection and genotyping
Fifty-four SNPs in the NOS1, NOS2, and NOS3 genes were
selected. Six were selected based on the literature (ie, previously
reported association with FENO, asthma, and other respiratory
phenotypes) rs2682826,20 rs41279104,28 rs2255929,29
rs3918226,30 rs3918169,30 rs154975831 and were complemented
with 48 tagging SNPs to capture genetic variation across each
gene (supplementary table 1). Tag SNP selection was done using
the HapMap phase III European ancestry data (http://www.
hapmap.org) with a pairwise approach (r2$0.8) for SNPs with
minor allele frequency $0.05, extending to 100 kb upstream and
50 kb downstream of each gene. SNPs were genotyped using
Sequenom MassARRAY (Sequenom, San Diego, California,
USA) or a competitive allele speciﬁc PCR system, KASPar
(KBioscience, Hoddesdon, Hertfordshire, UK). SNPs with poor
genotype call rate (#95%) and deviation from HardyeWeinberg
Equilibrium (HWE) (p#0.05) were excluded.
Statistical analysis
In total, 1737 of 2084 European subjects had available FENO,
genotype, and covariate information and were included in the
analysis. Association between NOS polymorphisms and FENO
was analysed using ﬁve different genetic models: additive,
recessive, dominant, co-dominant (genotype speciﬁc risk) and
over-dominant (heterozygote risk).32
First, we performed a linear regression analysis for each SNP,
adjusting for age, sex, height, atopy, and smoking, where the
associated SNPs were identiﬁed and ranked according to statis-
tical signiﬁcance. Next we performed an analysis in two stages
using forward stepwise multiple linear regression analysis to
identify a reduced set of the strongest independently associated
SNPs and the most appropriate genetic model for each ﬁnal SNP.
In the ﬁrst stepwise analysis stage, SNPs with p#0.2 from the
additive genetic model in the single SNP association were
entered into the stepwise regression analysis, which aimed to
determine the most strongly associated SNP or SNPs in a model
allowing for independent effects of several SNPs.
In the second stage, signiﬁcant SNPs (p#0.05) from the ﬁrst
stage stepwise regression model, as well as any SNPs from the
initial single SNP association analyses with p#0.05 from any
non-additive (dominant, recessive, over-dominant and co-domi-
nant) genetic models, were included. This selection aimed to
ensure that genetic effects not following an additive model
would be adequately captured in this ﬁnal stage. All of the SNPs
thus selected and coded into all ﬁve genetic models were used as
input for a forward stepwise regression analysis in order to
identify the most predictive SNPs, each with the best-ﬁtting
genetic model, allowing for independent effects of several SNPs.
In both stepwise stages, the p value for an SNP covariate to
enter and remain in the model was set at p¼0.10 and p¼0.20,
respectively. The covariates age, sex, height, atopy, and smoking
were forced into the model. In the ﬁnal multi-SNP model, risk
genotype was deﬁned as the genotype that was associated with
higher levels of FENO.
Stratiﬁed analyses by asthma or atopy status, respectively,
were also performed for the ﬁnal SNP model. The genetic effect
was estimated separately for each stratum in a common inter-
action model, and interaction was tested by including appro-
priate interaction terms of NOS SNPs with asthma or atopy and
comparing models with and without interaction terms using
a likelihood ratio test. Models were adjusted for age, sex, height,
smoking, and asthma medication.
We also performed logistic regression analysis to examine the
association between identiﬁed risk genotypes and asthma and
atopy, respectively, under a dominant genetic model to optimise
statistical power. Finally, we analysed the relationship between
the risk genotypes and lung function (FEV1/FVC and per cent
predicted FVC and FEV1) using linear regression.
Single SNP association analyses were performed with the R
statistical package ‘SNPassoc’. Further regression analyses were
done using SAS V.9.2 (SAS Institute). FENO values were log
transformed before model ﬁtting. Estimated effects on FENO
and lung function are expressed as per cent difference relative to
a baseline category, and effects on asthma and atopy as ORs.
Values of p#0.05 were considered statistically signiﬁcant and
95% CIs were calculated for all effect estimates.
RESULTS
Baseline characteristics for the study population are presented in
table 1. Four SNPs had a genotype call rate #95% and one
showed departure from HWE (p¼0.03) and these were excluded
from analysis, leaving 49 SNPs (20 NOS1, 17 NOS2, and 12
NOS3). Minor allele frequencies, HWE p values and call rates are
shown in supplementary table 1. Linkage disequilibrium (LD)
plots for all three NOS genes are shown in supplementary
ﬁgures 1e3.
Thirteen SNPs with p#0.2 from the additive model in the
single SNP analysis (ﬁgure 1, supplementary table 2) were
entered into the ﬁrst stage stepwise regression analysis. This
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resulted in only one SNP, NOS2 rs9901734, signiﬁcantly
(p¼0.01) associated with FENO.
The SNP rs9901734 and seven SNPs with p#0.05 from non-
additive genetic models in the single SNP analysis (ﬁgure 1) were
entered into the second stage stepwise regression analysis. Two
SNPs in the NOS2 gene (rs9901734 and rs3729508) and one SNP
in the NOS3 gene (rs7830) were all signiﬁcantly associated with
FENO, each with different genetic models (table 2). For
rs9901734, subjects had 5.3% (95% CI 1.0% to 9.7%) higher
levels of FENO per each copy of the G allele (additive model). For
rs3729508, the optimal ﬁt was provided by a negative recessive
genetic effect model for the minor T allele, implying that
subjects with CC or CT genotype had 9.4% (95% CI 3.1% to
15.2%) higher FENO levels compared with TT genotype (ie,
dominant effect for the major C allele); and for rs7830, subjects
with GTor TT had 5.6% (95% CI 0.4% to 11.1%) higher levels of
FENO than GG genotype (dominant model).
Haplotype association analysis was performed for the two
NOS2 SNPs rs9910734 (C/G) and rs3729508 (C/T) using an
additive model. One haplotype (GC) was signiﬁcantly associated
with 9.1% higher levels of FENO (95% CI 2.8 to 15.8, p¼0.004)
per haplotype, compared to the baseline haplotype CC, with CT
and GT showing no effect versus CC.
When we stratiﬁed by asthma or atopy, the effect estimate for
NOS2 rs9901734 in ‘healthy’ subjects (ie, no asthma, wheeze or
atopy) was marginally strengthened and remained signiﬁcant.
The NOS2 rs3729508 estimate was slightly attenuated, while for
NOS3 rs7830 little effect was seen (table 3). In subjects with
asthma or atopy, the effect estimates were slightly weaker for
NOS2 rs9901734 and slightly stronger for NOS2 rs3729508,
although the difference was not signiﬁcant. ForNOS3, the rs7830
effect estimate was considerably stronger in asthmatics (21.9%,
95% CI 4.6% to 42.0%) and signiﬁcantly different from healthy
subjects (p for interaction¼0.01), but less so in atopic subjects.
No signiﬁcant association was found between the FENO
associated risk genotypes of NOS2 and NOS3 SNPs and asthma,
atopy or lung function parameters in our cohort (supplementary
tables 3 and 4). For future reference, the full results of our single
SNP association analyses for all 49 SNPs with FENO are shown
in supplementary table 5.
DISCUSSION
In this large Swedish study of an adult general population, we
have investigated genetic variation in the NOS genes, using
SNPs previously reported in the literature as well as tag SNPs. Of
the 49 NOS SNPs examined, two SNPs in NOS2 (rs9901734 and
rs3729508) and one SNP in NOS3 (rs7830) were independently
associated with variation in FENO levels. The association
between rs7830 and FENO varied by asthma status.
The NOS2 gene, also known as inducible NOS, is a priori the
most obvious candidate for affecting levels of FENO associated
with airway inﬂammation. A recent population based study,
conducted in California, USA by Salam et al, provided strong
evidence in Hispanic and non-Hispanic white children
supporting the proposal that polymorphisms in NOS2 are
important determinants of exhaled NO.21 They found four SNPs
in particular to be most strongly associated with levels of FENO.
Our dataset included two SNPs (rs2248814 and rs4795051) in
high LD (based on 1000 Genomes Project) with three of their
identiﬁed SNPs (rs2297512, rs2274894, and rs8081248), and both
had the same direction of effect and were signiﬁcant in our
single SNP association analyses (rs2248814: FENO �5.23%, 95%
CI �8.6% to �1.9%, p¼0.002; rs4795051: FENO �5.1%, 95% CI
�8.3% to �1.8%, p¼0.003; supplementary table 6). On the
other hand, our top NOS2 SNPs from the stepwise analysis
(rs9901734 and rs3729508) both showed low LD (r2#0.50) to
the four top SNPs in the study by Salam et al.21 Conversely, they
had two other SNPs that tagged one of our top SNPs (rs3729508)
perfectly, with highly concordant results (supplementary table
6). Overall, these concordant results provide strong evidence
that the NOS2 gene is likely to harbour variants affecting FENO
that are common to the studied populations and age groups, and
are also consistent with gene expression data showing that the
expression of NOS2 in human airway epithelium cells is an
Table 1 Basic characteristics of 1737 genotyped adults
from the Adonix study population, FENO levels overall and
in subgroups
Characteristic Mean (SD)
Age, years 49.2 (13.6)
Height, cm 172.3 (9.1)
FEV1/FVC ratio* 0.8 (0.1)
FVC (% predicted)* 97.1 (12.6)
FEV1 (% predicted)* 93.8 (13.6)
FENO levels, ppb
All (n¼1737) 15.9 (1.8)
Men (n¼853) 17.2 (1.7)
Women (n¼884) 14.7 (1.7)
Asthma (n¼298)y 17.3 (1.9)
Atopy (n¼432) 18.4 (1.9)
Never smokers (n¼878) 17.3 (1.7)
Former smokers (n¼534) 16.9 (1.7)
Current smokers (n¼325) 11.2 (1.8)
*Lung function data missing for 425 subjects.
yAsthma status missing for four subjects.
FENO, fraction of exhaled nitric oxide; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; ppb, parts per billion.
Table 2 Association of SNPs in NOS genes with FENO among adults
Gene/SNP Genetic model Genotypes
Prevalence,
n[1737
*Difference in
FENO (%), 95% CI p Value
NOS2
rs9901734 Additive CC (ref) 59% 0.016
CG 36% 5.3 (1.0 to 9.7)
GG 5% 10.7 (1.9 to 19.5)
rs3729508 Dominant TT (ref) 17% 0.004
CC+CT 83% 9.4 (3.1 to 15.2)
NOS3
rs7830 Dominant GG (ref) 40% 0.034
GT+TT 60% 5.6 (0.4 to 11.1)
*FENO values were expressed as percentage change, adjusted for age, sex, height, atopy, and smoking habits.
FENO, fraction of exhaled nitric oxide; NOS, nitric oxide synthase; SNP, single nucleotide polymorphism.
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important determinant of NO in exhaled breath.15 The results
also illustrate that although both we and Salam et al21 used a tag
SNP approach, important SNPs from both studies were not well
tagged in the other.
The constitutive form of NOS, particularly the NOS3 gene,
has previously been suggested to contribute to the variation in
FENO levels in asthmatics,19 20 33 including a missense poly-
morphism (G849T) which was reported to explain 16.3% of the
variation in levels of FENO in adult subjects with asthma.19 An
interaction between passive smoking and NOS3 (G849T) on
FENO has also been observed in children with asthma.33 Our
ﬁnding that both NOS2 and NOS3 are involved in regulating
FENO levels is novel. Recent experimental evidence has
emphasised an important interplay between NOS3 and NOS2.
Under inﬂammatory conditions, NOS3 knockout mice had an
impaired expression of NOS2 protein in airway epithelium
following an aerosol exposure.34 The rs7830 SNP that was
associated with higher levels of FENO in our study was located in
the NOS3 gene. Interestingly, our stratiﬁed results suggest that
asthma modiﬁes the association between rs7830 and FENO. The
effect estimate for rs7830 was substantially higher in asthmatics
than healthy subjects (21.9% vs 1.5% higher FENO for GT/TT vs
GG). These results thus support the idea that NOS3 plays a more
prominent role in contributing to genetic variation in FENO
levels in asthmatic than non-asthmatic subjects.
There was no clear association identiﬁed between any NOS1
SNP and FENO in our data. This is well in line with gene
expression data, where NOS2 is highly expressed in the human
lung, while NOS3 is expressed to a lesser extent and NOS1 is
undetectable.15
None of the SNPs selected from previous literature that we
examined was clearly associated with FENO in our study. Such
inconsistent results are, however, not entirely surprising given
differences across studies in factors such as genetic background
and environment. Furthermore, earlier studies generally only
investigated one or a few candidate SNPs, whereas we used
a relatively comprehensive set of tag SNPs to cover genetic
variation in the three NOS genes.
SNP rs9901734 is located in the intergenic region, close to
NOS2 (3 kb downstream), rs3729508 is located in the intronic
region of NOS2, and rs7830 is located in the 3-prime untrans-
lated region of NOS3. The function of these SNPs remains
unknown. They may inﬂuence levels of gene expression, directly
affecting variation in FENO. Alternatively, they may be in LD
with another coding or functional SNP or SNPs that actually
affect variation in FENO. Further studies of these NOS SNPs can
provide more information to better understand their role in
airway inﬂammation and respiratory health.
Our haplotype result is consistent with and provides
complementary information to our stepwise results. When the
two ‘risk’ variants (rs9901734 G allele and rs3729508 C allele) are
located on the same haplotype (GC), they appear to both mark
the same effect (ie, increase FENO levels). Carriers of this
haplotype are relatively common in the population (approxi-
mately 30%), with individuals carrying one haplotype having
increased FENO and individuals carrying two copies (homozy-
gotes) having even higher FENO levels compared to the
remaining population.
Although FENO has been used as a tool for the diagnosis
and management of asthma for more than a decade, it has not
yet fully found its place in the clinical setting. When trying to
use a single FENO measurement for guiding diagnosis, an
important obstacle is the large variation in ‘normal FENO
value’. We have previously endeavoured to establish normal
values for FENO based on FENO measurement from the same
population as in this study.35 Upper normal values (95th
centiles) ranged from 22 parts per billion (ppb) to 57 ppb in
different subgroups, depending on age, height, and presence of
atopy. FENO is most probably also associated with sex,36 but
this association was rather weak and did not reach statistical
signiﬁcance in this dataset. To date, the new normal values
have not been applied in any diagnostic study, so whether they
will improve the utility of FENO in the diagnosis of asthma is
still unclear. In the present study, individuals with all of the
studied risk genotypes in NOS2 and NOS3 (21% of population)
had on average 35% higher FENO than individuals with none
of the risk genotypes (4% of the population). At present it is
not possible to evaluate the FENO value in the scope of the
presence/absence of NOS polymorphisms in a clinical setting,
and the practical implications of the results are hence unclear.
With further development this may, however, become feasible,
which would enhance the interpretation of an individual
FENO value.
This study has several strengths. First, it was conducted on
a relatively large homogenous Swedish population sample and
was restricted to subjects of European origin, to limit population
stratiﬁcation. Second, we comprehensively evaluated common
genetic variation within all of the important human NOS genes
(NOS1, NOS2, and NOS3), by ﬁrst selecting SNPs with previous
evidence of relevance to airway inﬂammation, asthma, and other
respiratory diseases, and then using tag SNPs to complement
and achieve good coverage. Third, we applied a structured
approach to characterise details of the hypothesised association
between NOS genes and FENO, performing a forward stepwise
multiple linear regression analysis in two stages rather than
multiple testing, since our analysis was based on a clear prior
hypothesis. In the context of genetic association studies, step-
wise regression analysis has been proposed as a useful method to
select the most relevant typed variants, and thereby potentially
also capture effects of untyped causal functional polymorphisms
Table 3 Per cent change in the levels of FENO associated with NOS gene variants for healthy, asthmatic
and atopic subjects
Subgroup n[1737
NOS2 NOS3
p Value for interaction,
overall model*
rs9901734
(CG/GG vs CC)
rs3729508
(CC/CT vs TT)
rs7830
(GT/TT vs GG)
Healthyy n¼958 5.8 (0.6 to 11.1) 8.9 (0.6 to 17.8) 1.5 (�4.4 to 7.7)
Asthmatic n¼298 2.4 (�9.1 to 15.4) 11.3 (�9.1 to 36.4) 21.9z (4.6 to 42.0) 0.1
Atopic n¼432 3.8 (�5.5 to 14.0) 13.6 (�2.0 to 31.8) 4.9 (�6.5 to 17.7) 0.94
*Likelihood ratio test p value, comparing a model with to a model without interaction terms for all three SNPs simultaneously (3
degrees of freedom).
yHealthy ¼ no asthma, wheeze and atopy.
zSignificant interaction for NOS3 SNP rs7830 separately (P for interaction - rs7830*asthma¼0.01).
NOS, nitric oxide synthase; SNP, single nucleotide polymorphism.
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within the gene or, where sufﬁcient LD structure is present, also
in adjacent genes.37 We further extended this approach by
adding a second stepwise regression step to aid in identifying
most appropriate genetic models for each SNP that we observed
to be associated.
Some potential weaknesses of the present study should be
noted. According to the instrument manufacturer (Aerocrine
AB) the variability in FENOmeasurements is around 3 ppb. This
variability would induce some level of independent misclassiﬁ-
cation unrelated to genetic variation, and will on average tend to
slightly bias our results towards the null. A broad deﬁnition of
asthma was used, based on a questionnaire response with at
least one positive answer to one of several related questions
regarding asthma diagnosis and current active asthma, which
carries a potential risk of misclassiﬁcation. However, such
misclassiﬁcation of asthma is likely to be non-differential with
Figure 1 Single-SNP association between fraction of exhaled nitric oxide (FENO) and 49 single nucleotide polymorphisms (SNPs) in the three nitric
oxide synthase (NOS) genes (NOS1, NOS2, NOS3), by five different genetic models. Each circle represents the minus log10 of the p value for one
single NOS SNP for each genetic model. The horizontal dotted line shows a statistical significance level at p value 0.05. [¼SNPs with p#0.2 from
additive model. D¼ SNP with p#0.05 from at least one non-additive model.
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regard to genotypes, and would not account for the genetic
associations we observed, but may have contributed to decreased
statistical power in analyses involving the asthma phenotype.
Overall, our ﬁndings suggest that the observed genetic varia-
tion in exhaled NO levels between individuals in this study were
predominantly driven by the NOS2 (‘inducible NOS’, iNOS)
gene, indicating that NOS2 is the major NOS gene determining
variability in exhaled NO in healthy subjects. In asthmatics,
NOS3 (‘endothelial NOS’, eNOS) seemed to play a more
prominent role for FENO variation.
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Supplementary Tables and Figure 
Supplementary Table 1 Allele frequencies, Hardy-Weinberg equilibrium (HWE) p-values and 
call rates for 54 polymorphisms in the 3 NOS genes in the Adonix study population (n=1737). 
dbSNP id 
      Alleles 
(Major/Minor) 
Minor allele 
Frequency HWE p-value   
Call 
rate 
Previous 
Publications 
NOS1 SNPs  
     rs2682826* G/A 0.28 0.67 96.14 Leung et al., 2005 
rs816347 G/A 0.09 0.17 97.41 
rs2293054 G/A 0.28 0.47 97.12 
rs2293055 G/A 0.1 0.89 98.21 
rs9658350 A/G 0.19 0.52 92.74 
rs6490121 A/G 0.32 0.47 97.24 
rs2293050 C/T 0.4 0.48 98.04 
rs7977109 A/G 0.48 0.1 93.38 
rs7314935 G/A 0.12 0.58 97.64 
rs9658354 A/T 0.4 0.65 98.73 
rs532967 G/A 0.19 0.87 98.04 
rs7310618 C/G 0.11 0.26 98.04 
rs553715 G/T 0.4 0.27 98.27 
rs2077171 C/T 0.3 0.3 97.12 
rs545654 T/C 0.48 0.96 98.27 
rs12578547 T/C 0.24 0.03 95.1 
rs12424669 C/T 0.12 0.26 98.5 
rs1552227 C/T 0.28 0.68 98.39 
rs499262 C/T 0.19 0.28 90.9 
rs693534 G/A 0.4 0.96 97.64 
rs3782218 C/T 0.16 0.31 92.17 
rs1123425 A/G 0.43 0.55 97.98 
rs17509231 C/T 0.14 0.68 97.35 
rs9658253 C/T 0.19 0.53 98.16 
rs41279104* C/T 0.13 0.34 96.89  Djidjik et al., 2008 
      NOS2 SNPs 
     rs4795051 C/G 0.43 0.37 98.79 
rs9901734 C/G 0.23 1 98.56 
rs2255929* T/A 0.43 0.52 98.16 Hancock et al., 2006 
rs2297514 T/C 0.39 0.22 97.93 
rs2297515 A/C 0.14 0.48 97.41 
rs2248814 G/A 0.41 0.73 98.04 
rs2314810 G/C 0.05 1 98.5 
rs12944039 G/A 0.2 1 97.98 
rs4795067 A/G 0.37 0.6 98.16 
rs3729508 C/T 0.41 0.58 98.27 
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     rs4795051 C/G 0.43 0.37 98.79 
rs9901734 C/G 0.23 1 98.56 
rs2255929* T/A 0.43 0.52 98.16 Hancock et al., 2006 
rs2297514 T/C 0.39 0.22 97.93 
rs2297515 A/C 0.14 0.48 97.41 
rs2248814 G/A 0.41 0.73 98.04 
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rs944725 C/T 0.42 0.55 96.43 
rs8072199 C/T 0.48 0.11 96.2 
rs2072324 C/A 0.19 0.34 96.08 
rs3730013 G/A 0.32 1 98.04 
rs10459953 G/C 0.36 0.14 97.81 
rs2779248 T/C 0.39 1 97.7 
rs2301369 C/G 0.38 0.88 96.49 
 
      NOS3 SNPs 
     rs10277237 G/A 0.22 0.62 98.04 
rs1800779 A/G 0.35 0.12 97.64 
 rs2070744 T/C 0.36 0.12 98.16 
 rs3918226* C/T 0.08 0.3 98.39 Holla et al., 2006 
rs3918169* A/G 0.17 1 97.29 Holla et al., 2006 
rs3793342 G/A 0.16 0.59 97.98 
rs1549758* C/T 0.29 0.44 98.21 Holla et al., 2008 
rs1799983 G/T 0.29 0.35 98.16 
 rs3918227 C/A 0.09 0.89 97.98 
rs3918188 C/A 0.36 0.34 97.41 
 rs1808593 T/G 0.2 0.88 96.14 
 rs7830 G/T 0.38 0.17 98.04 
* SNPs previously reported to be associated with respiratory disease phenotypes. 
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Supplementary Table 2 Strongest P-values for the association of NOS gene SNPs with FENO 
for five different genetic models, selected to enter into stages I and stage II of stepwise 
regression in the statistical analysis. Selection criteria for additive genetic model results into 
stage I modelling was p≤0.2, and for non-additive genetic model results into stage II 
modelling p≤0.05 in any of the non-additive models.   
Gene 
 
dbSNP ID Additive Co-dominant Dominant Recessive Over-dominant 
NOS2 rs10459953 0.165      
NOS2 rs12944039 0.034      
NOS2 rs2072324 0.138      
NOS2 rs2248814 0.002 0.008 0.024 0.006   
NOS2 rs2255929 0.005 0.018 0.014 0.031   
NOS2 rs2297514 0.018  0.041    
NOS2 rs2301369 0.114      
NOS2 rs2779248 0.080  0.044    
NOS2 rs3729508 0.028 0.008  0.002   
NOS2 rs4795051 0.003 0.011 0.021 0.010   
NOS1 rs6490121 0.186      
NOS3 rs7830 0.053  0.044    
NOS2 rs9901734 0.001 0.005 0.001  0.009  
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rs944725 C/T 0.42 0.55 96.43 
rs8072199 C/T 0.48 0.11 96.2 
rs2072324 C/A 0.19 0.34 96.08 
rs3730013 G/A 0.32 1 98.04 
rs10459953 G/C 0.36 0.14 97.81 
rs2779248 T/C 0.39 1 97.7 
rs2301369 C/G 0.38 0.88 96.49 
 
      NOS3 SNPs 
     rs10277237 G/A 0.22 0.62 98.04 
rs1800779 A/G 0.35 0.12 97.64 
 rs2070744 T/C 0.36 0.12 98.16 
 rs3918226* C/T 0.08 0.3 98.39 Holla et al., 2006 
rs3918169* A/G 0.17 1 97.29 Holla et al., 2006 
rs3793342 G/A 0.16 0.59 97.98 
rs1549758* C/T 0.29 0.44 98.21 Holla et al., 2008 
rs1799983 G/T 0.29 0.35 98.16 
 rs3918227 C/A 0.09 0.89 97.98 
rs3918188 C/A 0.36 0.34 97.41 
 rs1808593 T/G 0.2 0.88 96.14 
 rs7830 G/T 0.38 0.17 98.04 
* SNPs previously reported to be associated with respiratory disease phenotypes. 
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Supplementary Table 2 Strongest P-values for the association of NOS gene SNPs with FENO 
for five different genetic models, selected to enter into stages I and stage II of stepwise 
regression in the statistical analysis. Selection criteria for additive genetic model results into 
stage I modelling was p≤0.2, and for non-additive genetic model results into stage II 
modelling p≤0.05 in any of the non-additive models.   
Gene 
 
dbSNP ID Additive Co-dominant Dominant Recessive Over-dominant 
NOS2 rs10459953 0.165      
NOS2 rs12944039 0.034      
NOS2 rs2072324 0.138      
NOS2 rs2248814 0.002 0.008 0.024 0.006   
NOS2 rs2255929 0.005 0.018 0.014 0.031   
NOS2 rs2297514 0.018  0.041    
NOS2 rs2301369 0.114      
NOS2 rs2779248 0.080  0.044    
NOS2 rs3729508 0.028 0.008  0.002   
NOS2 rs4795051 0.003 0.011 0.021 0.010   
NOS1 rs6490121 0.186      
NOS3 rs7830 0.053  0.044    
NOS2 rs9901734 0.001 0.005 0.001  0.009  
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Supplementary Table 3 Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.51) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
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Supplementary Table 4 Association between the identified risk genotypes of NOS SNPs and 
lung function parameters. 
      FEV1/FVC        FVC       FEV1 
Gene SNP Risk genotypes (%)* p   (%)* P   (%)* P 
NOS2 rs9901734 GG or CG −0.5 0.9 – 0.5 0.5 – 0.8 0.3 
NOS2 rs3729508 CC or CT 0.1 0.8 – 0.3 0.7 – 0.3 0.8 
NOS3 rs7830 GT or TT 0.4 0.3    0.2 0.8    0.7 0.4 
*% difference in FEV1/FVC and percent predicted FVC and FEV1, adjusted for age and smoking 
habits. FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity; 
 
 
 
 
 
 
 
 
Dahgam et al.                                                                                                   SNPs in NOS genes and FENO 
4 
 
 
Supplementary Table 3 Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.51) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Dahgam et al.                                                                                                   SNPs in NOS genes and FENO 
5 
 
Supplementary Table 4 Association between the identified risk genotypes of NOS SNPs and 
lung function parameters. 
      FEV1/FVC        FVC       FEV1 
Gene SNP Risk genotypes (%)* p   (%)* P   (%)* P 
NOS2 rs9901734 GG or CG −0.5 0.9 – 0.5 0.5 – 0.8 0.3 
NOS2 rs3729508 CC or CT 0.1 0.8 – 0.3 0.7 – 0.3 0.8 
NOS3 rs7830 GT or TT 0.4 0.3    0.2 0.8    0.7 0.4 
*% difference in FEV1/FVC and percent predicted FVC and FEV1, adjusted for age and smoking 
habits. FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity; 
 
 
 
 
 
 
 
 
D
ah
ga
m
 e
t 
al
.  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 S
N
Ps
 in
 N
O
S 
ge
ne
s a
nd
 F
EN
O
 
 
 Su
pp
le
m
en
ta
ry
 T
ab
le
 5
 R
es
ul
ts
 o
f s
in
gl
e-
SN
P 
an
al
ys
is
 o
f t
he
 4
9 
SN
Ps
 in
 th
re
e 
N
O
S 
ge
ne
s. 
Pe
rc
en
ta
ge
 d
iff
er
en
ce
 w
ith
 9
5%
 c
on
fid
en
ce
 in
te
rv
al
 o
f 
FE
N
O
 w
ith
 5
 d
iff
er
en
t g
en
et
ic
 m
od
el
s, 
ad
ju
st
ed
 fo
r a
ge
, s
ex
, h
ei
gh
t, 
at
op
y 
an
d 
sm
ok
in
g 
ha
bi
ts
 a
m
on
g 
17
37
 a
du
lt 
su
bj
ec
ts
 in
 th
e 
A
do
ni
x 
st
ud
y 
db
SN
P 
id
 
     
  A
lle
le
s 
(M
aj
or
/M
in
or
) 
A
dd
iti
ve
 
D
om
in
an
t 
R
ec
es
si
ve
 
O
ve
rd
om
in
an
t 
C
od
om
in
an
t 
(H
et
er
oz
yg
ot
e)
 
C
od
om
in
an
t 
(H
om
oz
yg
ot
e)
 
N
O
S1
 S
N
Ps
 
 
 
 
 
 
 
 
rs
26
82
82
6 
 G
/A
 
-2
.3
5(
-6
.1
6-
1.
61
) 
-2
.5
8(
-7
.3
3-
2.
42
) 
2.
17
(-1
2.
85
-5
.4
8)
 
0.
1(
-6
.3
8-
3.
65
) 
-2
.1
2(
-7
.1
2-
3.
14
) 
-5
.0
2(
-1
3.
91
-4
.7
7)
 
rs
81
63
47
 
 G
/A
 
-0
.5
1(
-6
.5
9-
5.
97
) 
0.
15
(-6
.2
4-
6.
96
) 
-1
9.
04
(-
43
.5
7-
16
.1
5)
 
0.
87
(-5
.6
3-
7.
82
) 
0.
75
(-5
.7
4-
7.
69
) 
-1
8.
94
(-
43
.5
2-
16
.3
2)
 
rs
22
93
05
4 
 G
/A
 
-0
.7
(-4
.4
7-
3.
21
) 
-1
.5
8(
-6
.3
3-
3.
41
) 
1.
46
(-7
.3
2-
11
.0
7)
 
-2
.0
9(
-6
.9
1-
2.
98
) 
-2
.0
1(
-6
.9
8-
3.
22
) 
0.
57
(-8
.3
8-
10
.4
) 
rs
22
93
05
5 
 G
/A
 
-0
.4
3(
-6
.0
4-
5.
51
) 
-0
.6
3(
-6
.6
4-
5.
77
) 
2.
17
(-2
0.
75
-3
1.
72
) 
-0
.7
9(
-6
.9
1-
5.
73
) 
-0
.7
7(
-6
.9
-5
.7
7)
 
2.
02
(-2
0.
89
-3
1.
58
) 
rs
64
90
12
1 
 A
/G
 
-2
.4
8(
-6
.0
4-
1.
22
) 
-3
.2
1(
-7
.9
1-
1.
72
) 
-3
.1
(-1
0.
56
-4
.9
8)
 
-2
.0
6(
-6
.8
4-
2.
97
) 
-2
.9
(-7
.8
7-
2.
33
) 
-4
.4
6(
-1
2.
16
-3
.9
1)
 
rs
22
93
05
0 
 C
/T
 
2.
21
(-1
.3
3-
5.
87
) 
4.
56
(-0
.6
7-
10
.0
6)
 
0.
31
(-6
.1
-7
.1
6)
 
4.
02
(-0
.9
8-
9.
28
) 
5.
05
(-0
.5
1-
10
.9
3)
 
3.
16
(-4
.0
9-
10
.9
6)
 
rs
73
14
93
5 
 G
/A
 
0.
8(
-4
.4
3-
6.
31
) 
1.
41
(-4
.3
2-
7.
47
) 
-5
.8
7(
-2
3.
89
-1
6.
42
) 
1.
95
(-3
.9
2-
8.
18
) 
1.
85
(-4
.0
3-
8.
09
) 
-5
.4
8(
-2
3.
61
-1
6.
95
) 
rs
96
58
35
4 
 A
/T
 
2.
13
(-1
.4
1-
5.
8)
 
4.
67
(-0
.5
5-
10
.1
6)
 
-0
.2
2(
-6
.6
5-
6.
66
) 
4.
44
(-0
.5
8-
9.
71
) 
5.
33
(-0
.2
4-
11
.2
) 
2.
77
(-4
.5
-1
0.
59
) 
rs
53
29
67
 
 G
/A
 
-2
.2
9(
-6
.5
3-
2.
14
) 
-2
.2
6(
-7
.2
1-
2.
95
) 
-5
.5
2(
-1
7.
15
-7
.7
5)
 
-1
.4
8(
-6
.6
1-
3.
93
) 
-1
.8
(-6
.9
5-
3.
64
) 
-6
.0
6(
-1
7.
72
-7
.2
5)
 
rs
73
10
61
8 
 C
/G
 
3.
42
(-2
.1
1-
9.
25
) 
4.
36
(-1
.8
1-
10
.9
2)
 
-1
.3
5(
-1
9.
56
-2
0.
97
) 
4.
75
(-1
.6
1-
11
.5
3)
 
4.
74
(-1
.6
4-
11
.5
3)
 
-0
.4
6(
-1
8.
86
-2
2.
11
) 
rs
55
37
15
 
 G
/T
 
0.
64
(-2
.8
1-
4.
22
) 
0.
85
(-4
.1
6-
6.
13
) 
0.
87
(-5
.5
5-
7.
73
) 
0.
3(
-4
.5
2-
5.
37
) 
0.
7(
-4
.6
2-
6.
32
) 
1.
27
(-5
.8
1-
8.
87
) 
rs
20
77
17
1 
 C
/T
 
-0
.4
1(
-4
.0
8-
3.
41
) 
0.
76
(-4
.1
-5
.8
6)
 
-4
.1
(-1
1.
81
-4
.2
7)
 
2.
31
(-2
.7
-7
.5
7)
 
1.
74
(-3
.4
3-
7.
19
) 
-3
.3
5(
-1
1.
41
-5
.4
4)
 
rs
54
56
54
 
 T/
C
 
-0
.2
3(
-3
.6
5-
3.
3)
 
-0
.8
2(
-6
.1
4-
4.
79
) 
0.
28
(-5
.4
5-
6.
36
) 
-0
.8
5(
-5
.6
2-
4.
15
) 
-1
.0
2(
-6
.6
4-
4.
93
) 
-0
.3
8(
-7
.1
-6
.8
2)
 
rs
12
42
46
69
 
 C
/T
 
1.
7(
-3
.6
3-
7.
33
) 
2.
39
(-3
.3
9-
8.
52
) 
-6
.0
2(
-2
5.
22
-1
8.
12
) 
2.
91
(-3
-9
.1
8)
 
2.
82
(-3
.0
9-
9.
1)
 
-5
.4
3(
-2
4.
78
-1
8.
91
) 
rs
15
52
22
7 
 C
/T
 
0.
39
(-3
.4
4-
4.
36
) 
0.
84
(-4
-5
.9
3)
 
-0
.7
7(
-9
.5
-8
.8
) 
1.
1(
-3
.8
3-
6.
3)
 
1.
06
(-4
.0
2-
6.
41
) 
-0
.3
1(
-9
.3
3-
9.
61
) 
rs
69
35
34
 
 G
/A
 
-1
.5
4(
-4
.9
8-
2.
02
) 
-1
.1
(-6
.0
3-
4.
09
) 
-3
.6
3(
-9
.9
4-
3.
13
) 
0.
94
(-3
.9
3-
6.
05
) 
-0
.2
1(
-5
.4
7-
5.
35
) 
-3
.7
4(
-1
0.
64
-3
.6
9)
 
rs
11
23
42
5 
 A
/G
 
0.
19
(-3
.3
-3
.8
1)
 
-0
.6
5(
-5
.7
4-
4.
72
) 
1.
62
(-4
.7
1-
8.
36
) 
-1
.5
(-6
.2
4-
3.
47
) 
-1
.2
(-6
.5
5-
4.
46
) 
0.
88
(-6
.1
8-
8.
47
) 
rs
17
50
92
31
 
 C
/T
 
-0
.4
4(
-5
.3
8-
4.
75
) 
-1
.3
6(
-6
.8
2-
4.
43
) 
8.
36
(-9
.4
3-
29
.6
4)
 
-2
.2
7(
-7
.8
3-
3.
62
) 
-2
.0
8(
-7
.6
7-
3.
84
) 
7.
82
(-9
.9
3-
29
.0
6)
 
 
 
 
 
 
 
 
 
Dahgam et al.                                                                                                   SNPs in NOS genes and FENO 
4 
 
 
Supplementary Table 3 Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.5 ) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
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Supplementary Table 4 Association between the identified risk genotypes of NOS SNPs and 
lung function parameters. 
      FEV1/FVC        FVC       FEV1 
Gene SNP Risk genotypes (%)* p   (%)* P   (%)* P 
NOS2 rs9901734 GG or CG −0.5 0.9 – 0.5 0.5 – 0.8 0.3 
NOS2 rs3729508 CC or CT 0.1 0.8 – 0.3 0.7 – 0.3 0.8 
NOS3 rs7830 GT or TT 0.4 0.3    0.2 0.8    0.7 0.4 
*% difference in FEV1/FVC and percent predicted FVC and FEV1, adjusted for age and smoking 
habits. FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity; 
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Supplementary Table 3 Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.5 ) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
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Supplementary Table 4 Association between the identified risk genotypes of NOS SNPs and 
lung function parameters. 
      FEV1/FVC        FVC       FEV1 
Gene SNP Risk genotypes (%)* p   (%)* P   (%)* P 
NOS2 rs9901734 GG or CG −0.5 0.9 – 0.5 0.5 – 0.8 0.3 
NOS2 rs3729508 CC or CT 0.1 0.8 – 0.3 0.7 – 0.3 0.8 
NOS3 rs7830 GT or TT 0.4 0.3    0.2 0.8    0.7 0.4 
*% difference in FEV1/FVC and percent predicted FVC and FEV1, adjusted for age and smoking 
habits. FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity; 
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Supplementary Table  Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.51) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
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Supplementary Table 4 Association between the identified risk genotypes of NOS SNPs and 
lung function parameters. 
      FEV1/FVC        FVC       FEV1 
Gene SNP Risk genotypes (%)* p   (%)* P   (%)* P 
NOS2 rs9901734 GG or CG −0.5 0.9 – 0.5 0.5 – 0.8 0.3 
NOS2 rs3729508 CC or CT 0.1 0.8 – 0.3 0.7 – 0.3 0.8 
NOS3 rs7830 GT or TT 0.4 0.3    0.2 0.8    0.7 0.4 
*% difference in FEV1/FVC and percent predicted FVC and FEV1, adjusted for age and smoking 
habits. FEV1: Forced Expiratory Volume in 1 sec; FVC: Forced Vital Capacity; 
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Supplementary Table 3 Association of the identified risk genotypes of NOS SNPs with asthma 
and atopy 
      Asthma   Atopy 
Gene SNP Risk genotypes OR* 95% CI   OR* 95% CI 
NOS2 rs9901734  GG or CG 1.16 (0.82-1.66) 0.83 (0.66-1.04) 
NOS2 rs3729508 CC or CT 1.07 (0.66-1.74) 0.93 (0.69-1.25) 
NOS3 rs7830 GT or TT 1.05 (0.73-1.51) 1.16 (0.92-1.47) 
* Adjusted for age, sex, height and smoking habits 
OR: odds ratio; CI: confidence interval. 
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ABSTRACT  
Background: Previous genetic association studies have reported evidence for association of 
SNPs in the inducible nitric oxide synthase (iNOS), encoded by the NOS2 gene to variation in 
levels of fractional exhaled nitric oxide (FENO) in children and adults. In this study we 
evaluated the region spanning from SNP rs4796017 (23.10 Mb) to rs2779248 (23.15 Mb) to 
further understand the contribution of  NOS2 to variation in levels of FENO. 
Methods: In a cohort of 5912 adults 25-75 years of age, we investigated the relationship 
between NOS2 haplotypes and FENO, and effect modifications by asthma. 
Results: Seven common haplotypes (H1-H7) were inferred from all possible haplotype 
combinations. One haplotype H3 was significantly associated with lower levels of FENO;  
-5.8% (95%CI -9.8 to -1.7; p=0.006) compared with the most common baseline haplotype H1. 
Three haplotypes (H2, H5 and H6) were significantly associated with higher levels of FENO, 
+4.2% (95%CI 0.6 to 7.8; p=0.02), +10.7% (95%CI 5.0 to 16.7; p=0.0002) and +14.9% 
(95%CI 10.6 to 19.3; p=7.8×10-13) respectively. The effect of haplotype (H3) was stronger in 
subjects with asthma ˗21.6% (95%CI, ˗33.5 to ˗5.9) than in subjects without asthma ˗4.2 
(95%CI ˗8.4 to 0.2). P-value for interaction between H3 and asthma status was 0.004. 
Conclusion: Our findings suggest several common haplotypes in the NOS2 gene are 
contributes to variation in FENO in adults. We also saw some evidence of effect modification 
by asthma status on haplotype (H3). 
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INTRODUCTION 
The fractional concentration of nitric oxide in exhaled air (FENO; fraction of exhaled NO) is 
suggested as a useful biomarker of airway inflammation [1]. Studies have shown increased 
levels of FENO in individuals with asthma [2, 3] and FENO correlates with eosinophilic 
airway inflammation while inhaled corticosteroids reduce FENO [1]. Increased levels of 
FENO can also be observed in adults and children without respiratory symptoms or asthma, 
and there are indications that increased FENO may be a marker of future risk of new onset of 
respiratory symptoms or asthma [4, 5].  
Nitric oxide (NO) is formed by conversion of L-arginine to L- citrulline in the presence of one 
of three distinct isoforms of NO synthase (NOS) known as neuronal NOS (nNOS;NOS1), 
inducible NOS (iNOS;NOS2) and endothelial NOS (eNOS;NOS3), coded by the three genes 
NOS1, NOS2 and NOS3, respectively [6]. nNOS and eNOS each generate small amounts NO 
in the lung. iNOS on the other hand generates substantial amounts of NO primarily in 
response to inflammatory stimuli such as cytokines, oxidants and infections [7]. The 
expression of NOS2 in human airway epithelium cells is regulated by various inflammatory 
(e.g. nuclear factor kappa B (NFκB)) and non-inflammatory (e.g. Kruppel-like factor) 
transcriptional factors suggesting that several diverse pathways are involved [7, 8]. A gene 
expression study has demonstrated that enhanced expression of the NOS2 gene in the 
epithelial cells of the airways is related to increased FENO levels in healthy individuals [9]. 
Genetic association studies in both children and adults have reported that polymorphisms in 
the NOS2 gene influence levels of FENO  [10-12]. In a previous study we reported two 
tagging SNPs in NOS2, rs9901734 and rs3729508, that were associated with FENO levels in 
adults without asthma or respiratory symptoms or atopy [12]. A recent study by Bouzigon et 
al also provided evidence of a relationship between SNPs in the NOS2 gene and FENO in 
non-asthmatic adults [11]. In an earlier by Salam et al. have identified comprehensive sets of 
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haplotypes in the promoter, coding and downstream regions in NOS2 and found associations 
of these haplotypes with FENO in children with and without asthma. However, important 
details about the contribution of the NOS2 gene to variation in FENO levels are still lacking. 
In this study, we fine mapped the previous findings by others and us to identify sequence 
specific combinations of alleles (haplotypes) that influence FENO levels.  
MATERIALS AND METHODS 
Study population: We used the population-based Adult Onset Asthma and Nitric Oxide 
(ADONIX) cohort of men and women, aged 25-75 years at the time of sampling and recruited 
between 2001 and 2008 in Gothenburg, Sweden. The ADONIX cohort includes in total 6679 
participants. Part of the study population (1737 subjects) recruited during 2001-2003 were 
also included in our previous work on the NOS genes and FENO[12]. 
The original study design and protocol of the ADONIX study has been described in detail 
elsewhere [13, 14]. In brief, all participants received a questionnaire related to current 
respiratory health status, medical history and smoking habits. Participants who responded to 
the questionnaire were also invited for clinical examination, which included blood sampling 
and measurements of FENO. In the present study, asthma was defined based on a positive 
answer to at least one of the questionnaire items: 'Have you ever had asthma?'; 'Have you ever 
had asthma diagnosed by a doctor?'; 'Have you had an attack of asthma during the last 12 
months?'; 'Do you having asthma during the past month?' Atopy was defined as the presence 
of specific serum IgE antibodies (≥0.35 kU/1) to any of eight common inhaled allergens (dog, 
cat, horse, timothy grass, birch, mugwort, house dust mite, and cladiosporum) as determined 
by the Phadiatop test (PharmaciaDiagnostics; Uppsala, Sweden) [15]. Participants were 
classified as smokers or non-smokers based on their reported smoking habits. 
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Measurements of FENO: FENO was measured with an online NO monitoring system 
(NIOX® ; Aerocrine AB, Stockholm, Sweden), at an exhalation flow of 50 ml/s, according to 
the 2005 ATS/ERS recommendations [16], after at least 4 hours of fasting. Exhalations were 
registered for each subject within 10% deviation, and in triplicate between June 2001 and 
January 2003, and in duplicate from February 2003 through 2008 according to the revised 
ATS/ERS recommendations [16]. The mean concentration was used for analyses.  
SNP selection and genotyping: Ten SNPs in the region spanning from 23.10 Mb to 23.15 Mb 
of the NOS2 gene (the NCBI build 36) were selected for analysis based on previously published 
data regarding their association with FENO (table 2) [10, 12]. Six SNPs (rs9901734, 
rs2297514, rs2248814, rs12944039, rs3729508 and rs2779248) were main findings from our 
previous analysis [12]. The remaining four SNPs (rs4796017, rs2297520, rs9895453 and 
rs10459953) were SNPs from the Salam et al Southern California Children’s Health Study that 
were not in close LD with our earlier findings [10]. SNPs were genotyped using a Sequenom 
MassARRAY platform (Sequenom San Diego, CA, USA) or a competitive allele specific PCR 
system, KASPar (KBioscience, Hoddesdon Herts, Great Britain). Genotyping call rate for all 
SNPs was ≥98% and all the SNPs were in Hardy-Weinberg Equilibrium (HWE) (p≥0.001). 
Samples with genotyping success rate ≤80% across the 10 SNPs were excluded from the study. 
Only subjects reporting European country of birth were included in the present study; 96% 
were of Swedish origin. 
Statistical analysis: Stepwise regression in a forward approach was performed in SAS 
(Version 9.2, SAS Institute) assuming five different genetic models as previously described 
[12], to find a subset of SNPs in the NOS2 gene that were strongly associated with FENO. In 
the stepwise regression analysis, p-values were set to 0.10 and 0.20 for a SNP to enter and 
remain in the model, respectively. Subsequently, we considered SNPs with a p-value of 
≤0.005 from the stepwise regression for haplotype association analysis. We obtained all 
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possible haplotype pairs along with their respective likelihoods for each individual, and 
resulting population frequencies using an E-M (expectation-maximization) algorithm as 
implemented in the 'haplo.stats' package in the R statistical program [17]. The E-M algorithm 
estimates haplotype frequencies and posterior probabilities of each pair of haplotypes in each 
individual given observed genotypic data using a likelihood approach. A generalized linear 
model using the haplo.glm function implemented in the 'haplo.stats' package was used for 
estimating the effect of all common haplotypes (haplotype frequencies ≥5%) on levels of 
FENO, using the most common haplotype as the reference group, assuming an additive 
genetic model. We evaluated the haplotype effects on FENO by asthma status, by including 
product term between the haplotypes and asthma in the main effect model.  
Since the distribution of FENO was skewed, values were log-transformed prior to analyses. We 
adjusted all the analyses for age, sex, height, atopy and smoking habits. Results are presented 
as a percentage change in the geometric mean of FENO across group of subjects, comparing 
each SNP or haplotype to the respective reference. 
RESULTS 
In the total cohort (n=6679), DNA was available for 6340 participants. Of these, 5963 (94%) 
were of European origin and 377 (6%) of non-European origin. We excluded fifty-one 
individuals due to poor genotyping quality, leaving 5912 European participants. Among these, 
5633 participants had FENO values and constituted the final analysis set. Basic characteristics 
of the study population and FENO levels are presented in Table 1. Geometric mean (±SD) of 
FENO level was 16.4 (±1.8) parts per billion (ppb) for all subjects. Descriptive statistics and 
publication source of the ten SNPs are shown in Table 2. The LD pattern of the ten SNPs in the 
NOS2 gene, with corresponding r2 values are shown in supplementary Figure 1. 
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The stepwise analysis identified a subset of five SNPs with independent associations with 
FENO (Table 3). The minor allele of one SNP, rs3729508(C/T), showed a negative 
association, and the other four SNPs (rs4796017(C/G), rs9901734(C/G), rs9895453 (T/C) and 
rs2779248 (T/C)) showed positive association for the minor allele, with different genetic 
models.  
Seven common haplotypes, each with a frequency of ≥5% in the population, accounted for 
84% of all possible haplotype combinations, and rare haplotypes for approximately 16%. The 
haplotypes and their frequencies defined by the subset of 5 SNPs are presented in Table 4. 
The most common haplotype 'ACTCT ' was chosen as the baseline haplotype (H1). We found 
significant associations between four haplotypes (H2, H3, H5 and H6) and FENO (Table 4). 
Haplotypes H2 (ACCTC), H5 (GGCTC) and H6 (GGCTT) were significantly associated with 
higher levels of FENO, +4.2% (95%CI 0.6 to 7.8; p=0.02), +10.7% (95%CI 5.0 to 16.7; 
p=0.0002) and +14.9% (95%CI 10.6 to 19.3; p=7.8 × 10-13), respectively, compared with the 
baseline haplotype. Haplotype H3 (ACCTT) was significantly associated with lower levels of 
FENO, ˗5.8% (95%CI -9.8 to -1.7, p=0.006). 
Among subjects with asthma, H2, H4, H5 and H7 were associated with lower FENO values 
while an opposite effect was observed among subjects without asthma. For H6 the effect was 
positive in both groups, but stronger in subjects with asthma. However, these differences were 
statistically not significant. There was a statistically significant difference in the association 
between H3 and FENO in subjects with asthma as compared to in subjects without asthma (p-
value for interaction=0.004), with a more strongly negative effect in subjects with asthma 
than in subjects without asthma [˗21.6, 95%CI ˗33.5, ˗5.9 vs ˗4.2, 95%CI ˗8.2, 0.2) Table 5. 
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DISCUSSION 
In this study of Swedish adults, we identified four haplotypes in the NOS2 gene that were 
strongly and significantly associated with levels of FENO in adults. One haplotype (H3) was 
associated with lower FENO and the three other (H2, H5 and H6) with higher FENO. In 
addition to the main effects, we also observed an effect modification by asthma status for 
association with haplotype H3.  
The human NOS2 gene is one of several genes encoding a NOS enzyme isoform, and it has 
been demonstrated that expression of this isoform was associated with exhaled NO levels in 
children [9]. So far, only our previous study and two others have attempted to study 
association between polymorphisms in the NOS2 gene and FENO levels in either adults or 
children [10-12]. In children, various SNPs including rs2297512, rs2774894, rs8081248 and 
rs4796017 (Salam et al. [10]) and in adults rs9901734, rs2297514 (Dahgam et al. [12]), and 
most recently rs12601458, rs6505510 (Bouzigon et al. [11]) have been reported to be 
associated with FENO among subjects without asthma. In our analysis, of the 10 investigated 
SNPs selected from our study and Salam et al. five showed significant, and independent, 
evidence of association with FENO levels. This result is in line with the most recent report 
from the French Epidemiological study on the Genetics and Environment of Asthma (EGEA) 
assessing effects of genetic variants of the NOS genes on exhaled NO among non-asthmatic 
adults [11]. However, direct experimental evidence to support a functional role of the studied 
NOS2 polymorphisms is currently lacking. 
Haplotype analysis, which may provide additional information beyond individual SNP 
analysis about the genetic basis of complex traits and can be helpful in understanding the unit 
of biological function, has become of more widespread interest in finding casual connections 
in candidate genes studies. [18-20]. Furthermore, constructing haplotypes from a subset of 
                                                                                                                     
9 
 
informative SNPs reduces the haplotype dimensionality and increases power for detecting 
associations as compared to separate analysis of individual SNPs [20-22]. Using this approach 
in our study five-SNP haplotype analysis revealed four haplotypes with strong and significant 
association with FENO. Although significant associations were found also for individual 
SNPs, the haplotype analysis revealed very strong associations, and the haplotype model 
provided a much stronger global p value (3.8×10-28) for association than individual SNPs. Our 
results generally support the findings in children with and without asthma by Salam et al. who 
also report several haplotypes of NOS2 that were associated with increased FENO levels. 
However, Salam et al [10] used a population-based sample of children that were partly of 
European and non-European ancestry (non-Hispanic white and Hispanic white), and another 
set of SNPs to infer all possible haplotypes that occurred to describe variation in levels of 
FENO. So neither the two study populations nor the haplotype analysis methods are entire 
comparable. 
This study extends our previous work on FENO association. Strengths of this study include a 
large study sample from a homogenous adult population and a strong biological a priori 
hypothesis. In addition, haplotypes were inferred from a set of SNPs with previously reported 
association with FENO rather than by just selecting random tag SNPs. Finally, non-European 
subjects were excluded from the analysis to avoid potential confounding effects of population 
stratification.  
Our findings thus suggest that the haplotype structure across the NOS2 gene contributing to 
variation in FENO in adults. Furthermore, we demonstrated that the effect of some of these 
haplotypes differ by asthma status. The SNPs we used to infer the haplotypes are not located 
in coding or promoter regions. Potential biological reasons for our results could be that the 
haplotypes are in strong LD with unmeasured causal genetic alterations or that they are 
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involved in more complex regulation of gene expression [20]. Further studies can be build on 
these findings to search for causal genetic variants with respect to the studied gene region. 
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Tables  
Table 1. Baseline characteristics of the study population (n=5633) and FENO levels overall 
and in subgroups. 
Variable Mean (±SD) 
Age, years 52 (±11.7) 
Height, cm 173 (±9.2) 
  FENO50 levels, ppb 
 All (n=5633) 16.4 (±1.8) 
Men (n=2686) 18.2 (±1.8) 
Women (n=2947) 14.9 (±1.8) 
                            Smokers (n=959) 11.4 (±1.8) 
                            Non-smokers (n=4674) 17.6 (±1.7) 
                           Asthma (n=726) 17.7 (±2.1) 
                           Atopy (n=1340) 18.9 (±1.9) 
FENO: fractional of exhaled nitric oxide; ppb: parts per billion.  
Table 2. Summary of genotyped single nucleotide polymorphisms (SNPs) in the NOS2 gene.  
rs-number 
(dbSNP) 
Major/minor  
allele SNP position‡ 
SNP  
location MAF(%) 
 HWE 
p-value 
Previous 
 publications 
rs4796017 A/G 23099118 Intergenic 43.6 0.13004 Salam et al 2011 
rs9901734* C/G 23105156 Intergenic 23.3 0.381615 Dahgam et al  2012 
rs2297514† T/C 23117442 Intron 40 0.22077 Dahgam et al  2012 
rs2248814† G/A 23124448 Intron 40.6 1 Dahgam et al  2012 
rs12944039† G/A 23128891 Intron 21.2 0.784704 Dahgam et al  2012 
rs2297520 C/T 23132167 Intron 40.2 0.54992 Salam et al 2011 
rs3729508* C/T 23133157 Intron 40.3 0.786645 Dahgam et al  2012 
rs9895453 T/C 23134884 Intron 47.7 0.834329 Salam et al 2011 
rs10459953 G/C 23151645 UTR-5ʹ 35.7 0.55049 Salam et al 2011 
rs2779248† T/C 23151959 Near-gene-5‖ 38.5 0.868869 Dahgam et al  2012 
NOS2: inducible Nitric oxide synthase; MAF : Minor allele frequency; HWE: Hardy-Weinberg 
Equilibrium; * Top SNPs associated with FENO in multi-SNP analysis and † strongest p-values for 
association with FENO in single-SNP analysis in our previous work [12]. All SNPs are oriented to the 
forward strand of the NCBI build 36. ‖ Intergenic, but within 2000 bases of a transcribed region.  
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Table 3. Effect of gene variants of NOS2 on levels of FENO. Results from the stepwise 
regression with different genetic models.  
dbSNP Genotype  
Prevalance   
(%) 
Genetic 
model 
% Change in  
FENO, (95%CI)      P-value 
rs4796017 AA‡ 32.5 
Additive 
  
 
AG 48.5 
  
 
GG 19.2 4 (1.1,6.7)* 0.00542 
      rs9901734 CC‡ 59.2 
Dominant   
 
CG+GG 40.8 7.8 (3.9,11.8) 0.00006 
      rs3729508 CC‡ 35.5 
Additive 
  
 
TC 48.3 
  TT 16.2 ˗12.7(-12.7,-17.3)* <0.0001 
      rs9895453 TT‡ 27 
Additive 
  
 
TC 56.4 
  CC 22 10.5(6.1,15.2)* <0.0001 
      rs2779248 TT‡ 37.8 
Dominant     TC+CC 62.2 6.3 (2.6,10.1) 0.00074 
iNOS:NOS2: Inducible Nitric oxide synthase. FENO: Fraction of exhaled nitric oxide.‡ Reference 
genotype. *Effect per minor allele.  
 
 
Table 4. Association between haplotypes of the NOS2 gene and levels of FENO (n=5633): 
Main effect model. 
Haplotypes rs4796017 rs9901734 rs3729508 rs9895453 rs2779248 
 
Frequency 
(%) 
% Change in 
FENO, 
(95%CI)    p-value 
H1(Baseline) A C T C T 30                    Reference 
H2 A C C T C 14 4.2 (0.6,7.8) 0.02 
H3 A C C T T 9 ˗5.8 (-9.8,-1.7) 0.006 
H4 G C C T C 10 3.6 (-0.3,7.7) 0.07 
H5 G G C T C 5 10.7 (5.1,16.7) 0.0002 
H6 G G C T T 10 14.9 (10.6,19.3) 7.8×10-13 
H7 G G T C T 6 3.2 (-2.3,8.9) 0.26 
Rare * * * * * 16 16 (12.3,19.8) <0.001 
FENO: Fraction of exhaled nitric oxide; NOS2:iNOS: Inducible Nitric oxide synthase; CI confidence 
interval. Effects of haplotype on FENO was expressed as percentage difference in levels of FENO 
compared with most common haplotype .The model was adjusted for age, sex, height, atopy and 
smoking habits, assuming additive genetic model. P-value for global test for association: 3.88×10-28. 
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Table 5. Association between haplotypes of the NOS2 gene and levels of FENO, by asthma 
status.  
 
  Asthma status   
Haplotype 
Yes(n=726) 
% Change in FENO, 
(95%CI) 
No(n=4907) 
% Change in FENO, 
(95%CI) 
P-value 
for 
interaction(haplotype*asthma) 
 
(H2)ACCTC ˗2.8(˗16.5,12.2) 5.3(1.5,9.2) 0.138 
(H3)ACCTT ˗21.6(˗33.5,˗5.9) ˗4.2(˗8.4,0.2) 0.004 
(H4)GCCTC ˗5.6(˗20.2,10.5) 4.9(1.0,9.4) 0.075 
(H5)GGCTC ˗1.6(˗22.8,21.4) 12.1(6.0,18.5) 0.092 
(H6)GGCTT 24.3(7.6,47.1) 13.8(9.4,18.5) 0.091 
(H7)GGTCT ˗6.4(˗26.1,17.4) 3.8(˗2.0,9.9) 0.224 
FENO: Fraction of exhaled nitric oxide; NOS2:iNOS: Inducible Nitric oxide synthase; CI confidence 
interval .The model was adjusted for age, sex, height, atopy and smoking habits, assuming additive 
genetic model. Effect modifications were calculated as follows: when asthma = Yes, the effect of 
haplotype is β coefficient of haplotype+ β coefficient of interaction term, and when asthma = NO, the 
effect of haplotype is β coefficient of haplotype. SNPs order in haplotypes: rs4796017, rs9901734, 
rs3729508, rs9895453 and rs2779248. 
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Supplementary figure  
 
Supplementary figure 1. Linkage disequilibrium (LD) map of 10 SNPs in NOS2 gene on 
chromosome 17. The number in each box corresponds to the pairwise correlation coefficient r2 (a 
measure of LD) between any two SNPs and shading indicates D' (a measure of LD; red shade 
indicates high D' and light red shade indicates low D').  
 
